[go: up one dir, main page]

WO1999065520A1 - Proteines de la surface de l'ovocyte et methodes de modulation de la fecondite - Google Patents

Proteines de la surface de l'ovocyte et methodes de modulation de la fecondite Download PDF

Info

Publication number
WO1999065520A1
WO1999065520A1 PCT/US1999/013858 US9913858W WO9965520A1 WO 1999065520 A1 WO1999065520 A1 WO 1999065520A1 US 9913858 W US9913858 W US 9913858W WO 9965520 A1 WO9965520 A1 WO 9965520A1
Authority
WO
WIPO (PCT)
Prior art keywords
egg
plc
sperm
egg surface
protein
Prior art date
Application number
PCT/US1999/013858
Other languages
English (en)
Inventor
John C. Herr
Scott A. Coonrod
Original Assignee
University Of Virginia Patent Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Virginia Patent Foundation filed Critical University Of Virginia Patent Foundation
Priority to EP99930430A priority Critical patent/EP1085903A1/fr
Priority to AU46974/99A priority patent/AU4697499A/en
Priority to JP2000554398A priority patent/JP2002518344A/ja
Publication of WO1999065520A1 publication Critical patent/WO1999065520A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/367—Infertility, e.g. sperm disorder, ovulatory dysfunction

Definitions

  • the present invention is directed to egg surface antigens useful for producing 15 antibodies which bind epitopes on the egg surface and modulate fertility.
  • the invention encompasses compositions and methods for immunizing an individual for production of antibodies against egg surface antigens.
  • the invention is based on the discovery of egg surface antigens involved in egg-sperm binding and fusion. Methods are provided for the use of such antigens in methods for sterilization of female animals. Methods are further 20 provided for the use of egg surface antigens to generate antibodies useful for temporary, reversible contraception methods. Methods are further provided for the use of anti-idiotypic monoclonal antibodies which mimic egg surface epitopes to actively immunize a mammal against pregnancy.
  • a contraceptive vaccine would provide many advantages over currently available methods of contraception.
  • Methods of contraception such as hormone therapies and chemical or mechanical barriers against fertilization have serious drawbacks, such as undesirable side effects and less than complete effectiveness.
  • side effects of hormonal therapies such as the pill include cancer, and in the case of mechanical barriers, increased susceptibility to infection.
  • contraceptive vaccines would further be useful for fertility control of animal populations, where long-term or permanent sterilization, without the need for frequent intervention, is desirable. For example, such long-term sterilization would be useful for controlling fertility in human beings or agriculturally important livestock, such as cattle and pigs.
  • contraceptive vaccines would be useful for permanent sterilization regimes useful for pest control, such as for sterilization of rodents or other unwanted populations. While there has been much interest in the development of immunocontraceptives, the focus has been, until recently, on the development of immunocontraceptives directed against sperm surface antigens, or on already known peptide hormones such as human chorionic gonadotropin and follicle stimulating hormone. One obstacle to the development of an effective egg surface antigen based immunocontraceptive vaccine has been the lack of knowledge regarding the molecular identities of egg surface proteins known to be directly involved in the fertilization process.
  • Mammalian fertilization may be defined as a series of gametic interactions in which capacitated sperm must first penetrate the cumulus cells and zona pellucida (the egg vestments), then bind to and fuse with the egg plasma membrane (oolemma).
  • the initial binding event between gametes is known as primary binding and occurs, in the mouse model, when the zona pellucida protein, ZP3, binds to a receptor(s) on the sperm (reviewed in (McLeskey et al., 1998, Int. Rev. of Cytol. 177: 57-113).
  • This binding event also initiates the acrosome reaction in which hydrolytic enzymes are released from the acrosomal compartment and act on the zona pellucida to facilitate penetration ofthe zona pellucida by sperm.
  • Zona penetration is known as secondary binding and is mediated by the zona protein, ZP2, and one or more molecules on the inner acrosomal membrane (reviewed in Snell and White, 1996, Cell 85: 629-637).
  • sperm Upon emergence from the zona pellucida, sperm then cross the perivitelline space and bind to and fuse with the oolemma.
  • the molecular basis of sperm-oolemma binding and fusion has yet to be fully elucidated; however, recent evidence has demonstrated that integrins are involved in the interaction. Almeida et al. (1995, Cell 81 : 1095-1104) found that when oocytes were treated with monoclonal antibodies against the egg surface integrin ⁇ 6 ⁇ l, mouse sperm-oolemma binding was reduced. Further, these investigators reported that somatic cells which express c ⁇ l bind mouse sperm avidly while somatic cells that lack ⁇ 6 or ⁇ l do not.
  • a proposed sperm surface ligand for ⁇ l is fertilin.
  • Fertilin contains a domain homologous to a family of integrin ligands known as disintegrins (Blobel et al., 1992, Nature 356: 248-252), which suggest a cell adhesion function for the molecule.
  • recombinant fertilin is known to bind to the oolemma (Evans et al., 1997, Dev. Biol. 187:79-93), with both monoclonal antibodies to fertilin (Primakoff et al., 1987, J. Cell. Biol.
  • protein DE protein DE
  • Glycosyl-phosphatidylinositol (GPI)-anchored proteins may play a key role in gamete interaction.
  • GPI-anchored proteins possess a covalently linked glycosylated phosphatidylinositol moiety which serves to attach the protein portion ofthe molecule to the cell surface lipid bilayer (Low and Saltiel, 1988, Science, 239: 268-275).
  • Proteins linked to the cell surface via a phosphatidylinositol anchor are known to be involved in a wide variety of cellular functions including T cell activation, hydrolysis of extracellular matrix proteins, transduction of extracellular stimuli, and cell-cell adhesion (reviewed in Low and Saltiel, 1988, Science, 239: 268-275).
  • GPI-anchored proteins can be released from the cell surface by treatment of cells with the highly specific enzyme phosphatidylinositol- specific phospholipase C (PI-PLC) (Low and Finean, 1978, Bioch. Biophys. Acta. 508: 565-570). Therefore, treatment of intact cells with PI-PLC has become a useful tool to characterize the released proteins and to investigate the role of GPI-anchored proteins in cell function.
  • PI-PLC highly specific enzyme phosphatidylinositol- specific phospholipase C
  • Mouse sperm surface hyaluronidase (also known as PH-20) is a GPI- anchored protein and is thought to aid sperm in passage through the cumulus oopherous and possibly the zona pellucida by hydrolyzing the extracellular matrix protein, hyaluronic acid (Gmachl and Kreil, 1993, Proc. Nat. Acad. Sci. USA 90: 3569-3573); (Myles and Primakoff, 1997, Biol. Reprod., 56: 320-327).
  • SAGA-1 is another sperm surface protein which has been shown to be a GPI-linked.
  • GPI-anchored proteins on oocytes.
  • the hamster oocyte is unique in that zona-free eggs from other species such as the mouse, rat, and guinea pig do not incorporate heterologous sperm as readily
  • the present invention is directed to egg plasma membrane antigens useful for producing antibodies which will bind epitopes on the egg surface and modulate fertilization.
  • the invention is based on the discovery that egg surface GPI-anchored proteins are directly involved in egg-sperm fusion, a key step in fertilization.
  • the invention further encompasses compositions and methods for ⁇ immunizing an individual for production of antibodies against egg surface antigen(s).
  • the invention is based on the discovery of a conserved set of egg surface antigens, a subset of which are released from the follicular membrane upon treatment ofthe membrane with PI- PLC.
  • Methods are also provided for the use of antibodies against such antigens for active immunization, or sterilization, of female animals, by induction of a T-cell attack on the egg. 15 These methods are particularly useful in cases where permanent sterilization is desired, for example, for sterilization of animal populations.
  • Methods are further provided for the use of egg surface antigens to generate antibodies useful for passive immunization that can be used for reversible contraception methods.
  • Methods are further provided for the use of anti- idiotypic monoclonal antibodies which mimic egg surface epitopes to actively immunize a
  • the invention comprises a monoclonal antibody against an egg surface protein, novel hybridoma cells which express such antibodies; and methods for immunocontraception utilizing such monoclonal antibodies.
  • compositions comprising
  • Figure 1 PI-PLC treatment of gametes has no effect on sperm-zona pellucida binding, however, fertilization of zona-intact oocytes is blocked. Both sperm and eggs were separately treated with 1 U per ml PI-PLC for 30 min followed by gamete co-incubation in the presence of PI-PLC. To evaluate the effects of PI-PLC on sperm-zona binding, the ⁇ ⁇ oocytes were washed following 1 h gamete co-incubation and prepared for observation (see methods in Example in Section 6).
  • a single focal plane for each oocyte was selected in which the widest diameter ofthe zona pellucida could be visualized and the number of sperm in that focal plane was determined. No difference in sperm-zona pellucida binding was noted between the control group treated with inactivated PI-PLC (A) and the PI-PLC treated group (B). To evaluate the effects of PI-PLC on fertilization, the oocytes were washed following 2 h gamete co-incubation and incubated overnight. Following 24 h incubation, a significant decrease in the number of fertilized oocytes (as determined by cleavage) was noted in the treatment group (D) compared to the control group (C). In Figs.
  • Figure 2 Treatment of sperm with PI-PLC prior to incubation with zona-free oocytes has no effect on sperm-egg binding and fusion whereas treatment of eggs with PI-PLC inhibits sperm-egg binding and fusion.
  • Zona-free oocytes were pre-loaded with 1 ⁇ m Hoechst #33342 for 10 min and washed.
  • either sperm (A,B) or zona-free eggs (C,D) were treated with 1 U per ml PI-PLC for 30 min, washed, and the gametes were co- incubated for 40 min. The oocytes were then gently washed and prepared for observation (see methods in the Example given in Section 6).
  • Zona-free eggs were treated with either 5U per ml of heat inactivated PI-PLC, no PI-PLC, or increasing concentrations of PI-PLC for 30 min, washed and co-incubated with untreated sperm for 40 min. The oocytes were gently washed and prepared for observation (see methods in the Example in Section 6).
  • FIG. 4 Two-dimensional gel electrophoresis and silver staining reveals that the PI-PLC enzyme preparation is highly purified. One ⁇ g ofthe enzyme preparation was separated by two-dimensional electrophoresis and the gel was silver stained. Results show one prominent protein spot ( ⁇ MW 30 kDa, ⁇ pl 6) and several smaller protein spots immediately surrounding the prominent protein. See the Example in Section 6 for complete experimental details.
  • FIG. 5 Mouse eggs treated with PI-PLC can be artificially activated with calcium ionophore A23187.
  • Zona-free eggs were pre-loaded with Hoechst #33342, washed, and treated with PI-PLC for 30 min.
  • a small number of oocytes from the control group (A, inset) and treatment group (B, inset) were observed to ensure that oocytes had remained in metaphase II arrest following treatment.
  • Oocytes were then activated with 0.5 ⁇ m calcium ionophore A23187 for 5 min, washed and cultured for 40 min.
  • Figure 6 Treatment of zona-free oocytes with PI-PLC does not affect recognition of the ⁇ 6 ⁇ l integrin by its cognate antibody. Fluorescent beads (l ⁇ M) were coated with 6 ⁇ l antibodies then incubated with zona-free eggs that were either untreated or treated with 1 U er ml PI-PLC. No difference was observed in the number of anti- ⁇ l coated beads bound per egg when comparing the control group (A) with the PI-PLC treated group (B). Few beads bound when beads were coated with an equivalent concentration of control antibody and incubated with untreated eggs (C).
  • FIG. 7 Two-dimensional avidin blots of biotinylated egg surface proteins demonstrate that treatment of zona-free oocytes with PI-PLC releases 70 kDa (pi 5) and 35- 45 kDa (pi 5.5) protein clusters from the egg surface.
  • A The repertoire of sulfo-NHS biotin labeled surface proteins extracted from eggs which were not treated with PI-PLC. The 70 kDa (pi 5) and 35-45 kDa (pi 5.5) protein clusters (indicated by arrowheads) are PI- PLC sensitive. The three protein spots denoted by asterisks bind streptavidin-HRP non- specifically.
  • FIG. 8 (A-B)sperm-egg binding is significantly enhanced and sperm-egg fusion is not effected when human sperm are treated with PI-PLC and incubated with zona-free hamster oocytes.
  • Human sperm were treated with either 1 U/ml PI-PLC or 1 U/ml heat inactivated PI-PLC (95 °C, 5 mm) for 30 min, washed, and incubated with untreated zona-free hamster oocytes for 3 h. The oocytes were then gently pipetted to remove loosely bound sperm and the eggs were briefly incubated in acridine orange to stain chromatin.
  • the number of sperm bound per oocyte was then scored using phase contrast microscopy and sperm-egg fusion (B) was scored by counting the number of swollen sperm heads within each oocyte using fluorescent microscopy. Bars represent means +/- the standard deviation of three individual experiments.
  • FIG. 9 (A-B)sperm-egg binding and sperm-egg fusion is blocked when zona-free hamster oocytes are treated with PI-PLC and incubated with human sperm.
  • Zona-free hamster oocytes were treated with either 1 U/ml PI-PLC or 1 U/ml heat inactivated PI-PLC (95 °C, 5 min.) for 30 min, washed and incubated with untreated human sperm for 3h. The oocytes were then gently pipetted to remove loosely bound sperm and the eggs were briefly incubated in acridine orange to stain chromatin.
  • Figure 10 (A-B) Zona-free hamster oocytes can be artificially activated following PI-PLC treatment.
  • zona- free eggs were preloaded with Hoechst #33342, washed, and treated with either 1 U/ml PI- PLC or 1 U/ml heat inactivated PI-PLC (95 °C, 5 min) for 30 min.
  • Gocytes were then activated with 0.5 ⁇ m calcium ionophore A23 187 for 5 min, washed incubated at 37 °C and 5% CO 2 for 3h.
  • the eggs were considered activated if they had advanced from metaphase II arrest to anaphase II or telophase II (with second polar body). There was no observable difference in the number of eggs which resumed meiotic cell division in the group treated with inactivated PI-PLC (A) compared with the PI-PLC treated group (B). Arrows indicate extruded chromatin (stained blue) within the second polar body of oocytes from both groups. This experiment was repeated three times. Representative images were recorded using combined dual phase contrast and fluorescent microscopy (200X). Bar represents 20 ⁇ m.
  • Fi ure 11 Treatment ofzona-free hamster oocytes with PI-PLC releases a 25-40 kDa (pi 5-6) protein cluster from the oolemma.
  • Zona-free hamster oocytes were biotinylated, separated into two groups (130 oocytes per group), and either mock treated or treated with 1 U/ml PI-PLC.
  • the supernatants were collected, the eggs were washed, and the egg proteins were extracted in Celis buffer.
  • the egg protein extracts and the proteins from the supernatants were separated by 2-D electrophoresis and electroblotted to nitrocellulose membranes. The membranes were stained with Protogold to visualize the egg proteins (red staining).
  • C The repertoire of surface labeled oolemmal proteins following PI-PLC treatment. Arrows labeled c2 represent the location ofthe 25-40 kDa (pi 5-6) protein cluster which was prominent in extracts of mock treated oocytes.
  • D Supernatant from PI-PLC treated oocytes. Arrows indicate a 25-40 kDa (pi 5-6) protein cluster which has a mass and isoelectric point similar to that which is released from the oocyte following PI-PLC treatment. Asterisk indicates PI-PLC isoforms.
  • Figure 12 (A-B)
  • A Nucleotide sequence for the ZP3 human mRNA (SEQ ID NO:l).
  • B ZP3 amino acid sequence (SEQ ID NO:2) as derived from the nucleotide sequence of the ZP3 human mRNA.
  • Figure 13 Oolemmal ZP3 (A) partitions in the detergent phase of Triton-S 114 extracts whereas zona matrix ZP3 (B) partitions in the aqueous phase.
  • D detergent phase.
  • A aqueous phase.
  • FIG. 14 Localization of ZP3 to the oolemma of zona-free mouse oocytes. On the left a control rat IgG antibody was used; on the right anti-ZP3 (IE- 10) was used.
  • Kidney cells transfected with full length recombinant mouse ZP3 express ZP3 at the cell surface. Stained cells are shown at 200X magnification using phase contrast microscopy, and 200X and 630X using fluorescence microscopy.
  • Figure 16 (A-B Specificity ofthe IE- 10 mAb for oolemmal ZP3. Shown are without (A) or with (B) J peptide using contrast and fluorescent microscopy.
  • the present invention relates to identification of egg surface proteins, that can be used as immunogens in a vaccine preparation to aid in the modulation of fertility.
  • the invention relates to polypeptide antigens present on the egg plasma membrane.
  • Such antigens have been identified as molecules directly involved in egg-sperm fusion required for fertilization.
  • These specific glycosyl-phosphatidylinositol (GPD- anchored proteins are released from the egg plasma membrane by treatment of eggs with phosphatidylinositol-specific phospholipase C (PI-PLC). Release of this specific set of proteins results in a block to sperm-egg fusion and fertilization.
  • PI-PLC phosphatidylinositol-specific phospholipase C
  • the invention is directed to mouse egg plasma membrane polypeptides, herein called M70 polypeptides, that are involved in sperm-egg fusion.
  • M70 polypeptides ofthe invention encompass polypeptides which can be isolated from mouse egg which: 1) are located on the egg plasma membrane; 2) have a molecular weight of 70kDa; 3) have a pi of 5; 4) possess a covalently linked glycosylated phosphatidylinositol moiety; and 5) are specifically released from the egg plasma membrane upon treatment with phosphatidylinositol-specific phospholipase C (PI-PLC).
  • Other activities associated with such M70 polypeptides are antigenicity (ability to bind to an anti-M70 antibody or compete with M70 for binding), immunogenicity (ability to generate antibody which binds to M70).
  • the invention relates to polypeptides identified on the mouse egg plasma membrane, herein called M35/45 polypeptides, that are involved in sperm egg- fusion.
  • the M35/45 polypeptides ofthe invention encompass polypeptides which can be isolated from mouse egg which: 1) are located on the egg plasma membrane; 2) have a molecular weight of between 35 and 45 kDa; 3) have a pi of 5.5; 4) possess a covalently linked glycosylated phosphatidylinositol moiety; and 5) are specifically released from the egg plasma membrane upon treatment with phosphatidylinositol-specific phospholipase C (PI-PLC).
  • PI-PLC phosphatidylinositol-specific phospholipase C
  • M35/45 polypeptides migrate on polyacrylamide gels as a protein with a molecular weight of 35 kDa, 36kDa, 37 kDa, 38 kDa, 39 kDa, 40 kDa, 41 kDa, 42kDa, 43 kDa, 44 kDa, and 45 kDa,.
  • the invention relates to polypeptides identified on the hamster egg surface, herein called H25/40 polypeptides, that are involved in sperm egg- fusion.
  • the H25/40 polypeptides ofthe invention encompass polypeptides which can be isolated from hamster eggs which: 1) are located on the egg plasma membrane; 2) have a molecular weight of between 25 and 40 kDa; 3) have a pi of between 5 and 6; 4) possess a covalently linked glycosylated phosphatidylinositol moiety; and 5) are specifically released from the egg plasma membrane upon treatment with phosphatidylinositol-specific phospholipase C (PI-PLC).
  • PI-PLC phosphatidylinositol-specific phospholipase C
  • H25/40 polypeptides migrate on polyacrylamide gels as a protein with a molecular weight of between 25 and 30 kDa, or between 30 and 35kDa, or between 36 and 40 kDa.
  • the H25/40 polypeptides migrate on polyacrylamide gels as a protein with a molecular weight of 25 kDa, 26kDa, 27 kDa, 28 kDa, 29 kDa, 30 kDa, 31 kDa, 32kDa, 33 kDa, 34 kDa, 35 kDa, 36kDa, 37 kDa, 38 kDa, 39 kDa, and 40 kDa.
  • the invention relates to GPI-linked ZP3 polypeptide, or fragment or analog thereof.
  • ZP3 is a well known, highly conserved, zona pellucida polypeptide.
  • GPI-linked ZP3 is useful as a vaccine for sterilization or contraception of an animal or human subject.
  • An antigenic fragment of GPI-linked ZP3 can comprise a GPI moiety linked to 1-10 amino acids, 10-30 amino acids, 30- 80 amino acids, 50-100 amino acids, 100-200 amino acids, or 200-450 amino acids of ZP3.
  • the invention provides isolated M70, M35/40, and H25/40 polypeptide antigens.
  • the invention provides purified M70, M35/40, and H25/40 polypeptide antigens.
  • the GPI-linked ZP3 ofthe invention encompasses a GPI-linked ZP3 homolog or ortholog from any species.
  • a GPI-linked egg surface protein can comprise (A) the amino acid sequence shown in Fig. 12B (SEQ ID NO:2), or, (B) an amino acid sequence encoded by a DNA sequence that hybridizes to the complement ofthe DNA sequence of Fig.
  • the invention further relates to fragments (and derivatives and analogs thereof) of M70, M35/45, H25/40 and GPI-linked ZP3, which comprise one or more domains of an M70, M35/45, or H25/40 protein.
  • M70, M35/45, or H25/40 fragment is a glycolsylated phosphotidyinositol linked fragment.
  • M70, M35/45, or H25/40 fragment is an extracellular domain fragment.
  • egg plasma membrane polypeptides such as M70, M35/45, H25/40, and GPI-linked ZP3, bind to a sperm protein to facilitate sperm-egg fusion.
  • Egg plasma membrane polypeptides involved in sperm-egg fusion can be prepared for a variety of uses.
  • such polypeptides, or peptide fragments thereof can be used for the generation of antibodies, for use in diagnostic and therapeutic assays, or for the identification of agents or small molecules that modulate sperm-egg fusion process required for fertilization.
  • M70, M35/45, H25/40, and GPI-linked ZP3 can be purified from any cell type that expresses such polypeptides, such as mouse or hamster egg cells.
  • the M70, M35/40, and H25/40 polypeptides are purified from a fraction of an extract of such cells enriched for cell membrane components.
  • egg plasma membrane polypeptides, such as M70, M35/40, and H25/40 proteins can be solubilized from cells, or cell extracts, such as a cell membrane fraction.
  • solubilized proteins can subsequently be purified by various procedures known in the art, including but not limited to chromatography (e.g., ion exchange, affinity, and sizing chromatography), centrifugation, electrophoretic procedures, differential solubility, or by any other standard technique for the purification of proteins.
  • chromatography e.g., ion exchange, affinity, and sizing chromatography
  • centrifugation e.g., centrifugation
  • electrophoretic procedures e.g., electrophoretic procedures
  • differential solubility e.g., differential solubility
  • protein "spots" that appear in samples from normal eggs, but are absent in PI-PLC treated eggs can be analyzed further. Differences can be detected by visual inspection of gels, or by using densitometry and computerized image analysis thereby facilitating spot detection, background subtraction and spot matching (see Pennigton et al., 1997, Trends Cell Biol. 7: 168-73). Further, egg plasma membrane polypeptides, such as M70, M35/40, or H25/40 protein can be detected by Western Blot analysis of 2D gels, if antibody is available (Harlow and Lane, 1988, supra).
  • the molecular weight (MW) and the isoelectric point (pi) of an egg surface protein can be determined by calibrating its position relative to known standards run in parallel on 2D gels. Specific proteins can then be purified, and their sequence determined, or a portion of their sequence determined, by techniques well known in the art, such as Edman degradation sequencing (Edman and Begg, 1967, Eur. J. Biochem. 1 :80-91; see, e.g., Creighton, 1983, "Proteins: Structures and Molecular Principles," W.H. Freeman & Co., N.Y., pp.34-49), automated by electroblotting onto polyvinylidene difluoride (PVDF) membranes using Edman degradation chemistry
  • proteins and peptides can be characterized by mass spectrometry, using peptide-mass fingerprinting or protein sequencing methodologies to identify sequence information and post-translational modifications (Dainese et al., 1997, Electrophoresis,
  • the amino acid sequence obtained may be used as a guide for the generation of oligonucleotide mixtures that can be used to screen for gene sequences encoding such proteins.
  • the egg plasma membrane proteins ofthe present invention can be analyzed by assays based on their physical, immunological, or functional properties.
  • sequences of egg plasma membrane polypeptides involved in sperm-egg fusion can be derived by deduction from the DNA sequence if such is available, or alternatively, by direct sequencing ofthe protein, e.g., with an automated amino acid sequencer.
  • the protein sequences can be further characterized by a hydrophilicity analysis (Hopp and Woods, 1981, Proc. Natl. Acad. Sci. U.S.A. 78:3824-
  • a hydrophilicity profile can be used to identify the hydrophobic and hydrophilic regions ofthe protein (and the corresponding regions ofthe gene sequence, if available, which encode such regions).
  • a method ofthe invention for isolating M70, M35/40, or H25/40 protein comprises the steps of: a) preparing an extract of egg cells; b) contacting a M70, M35/40, or H25/40 specific antibody with the extract for a time period sufficient for the M70, M35/40, or H25/40 in the extract to bind the antibody; and c) recovering the bound antibody.
  • the method can also be used with an antibody that comprises an affinity tag. Accordingly, the method further comprises incubating the extract and the tagged antibody to the M70, M35/40, or H25/40 protein with a solid phase surface containing a binding partner ofthe affinity tag for a time period sufficient to allow binding ofthe egg plasma membrane polypeptides, such as M70, M35/40, or H25/40 to the solid phase surface prior to the recovery step. The isolated protein can then be eluted from the antibody.
  • Egg plasma membrane polypeptides such as M70, M35/40, and H25/40 can be purified by isolating cell membranes and purifying the egg plasma membrane polypeptides from other membrane components.
  • Membranes can be isolated from the egg cells ofthe invention, prepared according to the methods described in Section 6, below. Cells can be lysed and the plasma membrane fraction can be isolated from cells using procedures known in the art, such as dextran/polyethylene glycol biphase separation.
  • Plasma membranes can be treated with a buffer which dissociates membrane-associated proteins from the lipid bilayer (e.g., a buffer containing a non-ionic detergent such as Nonidet P-40TM, Triton X-100TM, or sodium deoxycholate). Proteins can be purified away from membrane lipids using conventional dialysis procedures.
  • the crude dialysed protein preparation can be applied to an affinity column composed of antibody or antiserum stabilized on an appropriate matrix.
  • Membrane-associated proteins other than M70, M35/40, or H25/40 will pass through the column, while M70, M35/40, or H25/40 will remain bound.
  • Non-specific binding of other membrane components can be reduced by increasing the salt concentration and varying the pH ofthe buffer in which the crude protein preparation is dissolved. Thorough washing of the column after application ofthe crude protein preparation can further reduce binding of non-specific proteins.
  • egg plasma membrane polypeptides such as M70, M35/40, or H25/40 protein may be purified using specific antibodies, previously generated against M70, M35/40, or H25/40 protein (see Section 5.7, infra), or cell membranes.
  • the crude protein preparation from membrane dialysis is applied to an antibody affinity column which is composed of M70, M35/40, or H25/40-specific antibody, stabilized on an appropriate matrix.
  • Antibody-coupled resin, or filter methods can also be used, or other antibody affinity techniques known in the art (see, for e.g., Harlow and Lane, 1988, supra).
  • the column or resin can be washed with buffer to remove proteins which bind non- specifically.
  • the protein which remains bound to the column is eluted by conventional procedure such as washing with a buffer containing high salt or low pH.
  • egg plasma membrane polypeptides such as
  • M70, M35/40, or H25/40 protein may be purified by sizing or ion exchange column chromatography. FPLC may be used to facilitate purification of large amounts of protein. If antibody to M70, M35/40, or H25/40 is generated or is available, protein may be detected and followed during purification by Western blot or ELISA (enzyme-linked immunosorbent assay) analysis.
  • FPLC ion exchange column chromatography
  • egg plasma membrane polypeptide nucleotide sequences ofthe invention can be isolated directly from mRNA, cDNA or from a cDNA or genomic library.
  • egg plasma membrane polypeptide cDNA can be isolated indirectly by first isolating and characterizing the egg plasma membrane polypeptide protein, and subsequently using the egg plasma membrane polypeptide sequence to identify gene sequences in a cDNA or genomic library. Details of such methods are fully described herein.
  • Nucleic acids encoding egg plasma membrane polypeptides involved in sperm-egg fusion can be isolated by a variety of methods well known to those of skill in the art, including, but not limited to: screening a cDNA expression library in mammalian cells using egg plasma membrane polypeptide specific antibodies, or "panning"; screening a cDNA expression library in bacterial cells; or differential expression methods such as screening a subtracted cDNA library with an egg plasma membrane polypeptide nucleic acid probe or a specific antibody.
  • RNA and cDNA preparation systems that are commercially available may also be used according to the manufacturer's instructions for making the mRNA and cDNA ofthe invention.
  • Total ribonucleic acid (RNA) may be isolated from egg cells by a variety of methods known in the art depending on the source and amount of cells. It is preferable to obtain good quality RNA that is of high molecular weight in order to construct cDNA libraries that contain even rarely expressed gene products. To prepare high quality RNA, methods that provide complete lysis of cells, and rapid inactivation of nucleases are preferred.
  • RNA preparation method uses the strong chaotropic agent, guanidinium isothiocyanate, with a mild detergent and 2-mercaptoethanol or dithiothreitol to denature proteins and inactivate nucleases, followed by purification ofthe RNA by ultracentrifugation (Chomczynski and Sacchi, 1987, Anal Biochem 162:156-159; Chomczynski, 1989, U.S. Patent No. 4,843,155). This procedure may also be used especially when isolating RNA from small quantities of cellular material.
  • RNA isolated from cells is further purified before conversion into complementary DNA (cDNA).
  • mRNA messenger RNA
  • poly- A poly(adenylic) acid
  • mRNA poly(adenylic) acid
  • oligo-dT cellulose Aviv and Leder, 1972, Proc. Natl. Acad. Sci., 69:1408-1412
  • Total RNA is denatured to expose the poly-A tails.
  • Poly-A+ RNA is then bound to oligo-dT cellulose, with the remainder ofthe RNA washing through.
  • the poly-A+ RNA is eluted by removing salt from the solution. This step may be repeated to further enrich for messenger RNA.
  • oligo-dT matrices in different configurations may also be used, including but not limited to, simple gravity columns, para-magnetic particles, and spin columns.
  • Substituted oligo-dT such as biotinylated oligo-dT, may also be used.
  • the quantity and quality of RNA thus obtained may be determined by methods such as formaldehyde agarose gel electrophoresis. The use of RNA enriched for poly-A+ RNA is most preferred.
  • RNA into double-stranded cDNA can be accomplished by a number of different procedures well known in the art. See for example, Okayama and Berg, 1982, Mol. Cell Biol. 2:161-170; Gubler and Hoffman, 1983, Gene 25:263-269; and Huse and Hansen, 1988, Strategies (Stratagene) 1:1-3.
  • the first step in the making of cDNA involves the oligonucleotide-primed synthesis of a first strand cDNA by reverse transcriptase.
  • mRNA hybridized to an oligo-dT primer can be copied into DNA by a reverse transcriptase, such as AMV reverse transcriptase, MMLV reverse transcriptase, or Superscript (Kotewicz et al, 1988, Nucleic Acid Res. 16:265-277). Random hexamers may be used to prime first-strand synthesis from internal sites within the mRNA instead of oligo-dT primers resulting in shorter cDNAs which are enriched for the 5' ends of long messenger RNAs.
  • a reverse transcriptase such as AMV reverse transcriptase, MMLV reverse transcriptase, or Superscript (Kotewicz et al, 1988, Nucleic Acid Res. 16:265-277). Random hexamers may be used to prime first-strand synthesis from internal sites within the mRNA instead of oligo-dT primers resulting in shorter cDNAs which are enriched for the 5' ends of long messenger RNAs.
  • the next step in the process involves synthesizing the second strand cDNA
  • the second strand cDNA may be synthesized using E. coli DNA polymerase I, Klenow fragment using the RNA-DNA as a template.
  • the RNA in the RNA-DNA hybrid can be removed with RNase H, and gaps in the newly synthesized second strand cDNA can be filled in by E. coli DNA polymerase I.
  • the fragments of second strand cDNAs thus
  • E. coli DNA ligase are ligated with E. coli DNA ligase to form a contiguous second strand cDNA.
  • the double stranded cDNA requires further repair with enzymes, such as RNase H, RNase A, T4 DNA polymerase and E. coli DNA ligase, to form perfectly matched strands (i.e., having "flush” or "blunt” ends).
  • the cDNA can be amplified in vitro, by nucleic acid amplification methods known in the art, such as polymerase chain reaction (PCR) and ligation-mediated chain reaction (LCR).
  • PCR polymerase chain reaction
  • LCR ligation-mediated chain reaction
  • first strand oligo-dT primed cDNA obtained by a standard method is extended with a oligo-dG tail by terminal transferase, and a second primer containing a oligo-dC segment is used to prime second strand synthesis with a thermostable DNA
  • RT-PCR can be used to generate amplified cDNAs from the RNAs (see, e.g., Domec et al, 1990, Anal Biochem, 188:422-426; Van Gelder et al, 1990, Proc. Natl. Acad. Sci., 87:1663-1667).
  • the egg plasma membrane polypeptide nucleic acid in another embodiment, the egg plasma membrane polypeptide nucleic acid
  • sequences can be isolated by identifying genes that are expressed in eggs but not in other cell types (such as sperm or somatic cells).
  • differential display can be used identify egg plasma membrane polypeptide cDNA sequences present in egg cells but absent in control cells.
  • Egg cells and negative control cells are prepared, and mRNA is isolated as described, supra.
  • cDNA is prepared from mRNA, as described, supra, using RT-polymerase chain amplification with a set of labeled oligonucleotide primers designed to identify the 3' ends of mRNAs (Liang and Pardee, 1992, supra).
  • Primers used for the synthesis ofthe first strand each contain a stretch of oligo dT at its 5' end, followed by a pair of nucleotides at its 3' end.
  • oligonucleotides are end-labeled and used as primers in reverse-transcriptase polymerase chain reactions (RT-PCR) to generate a population of specific cDNAs. Products of such RT-PCR reactions are displayed on a sequencing gel. Using mRNAs derived from different populations of cells, the pattern of displayed products can be compared to identify bands that are unique to different cell types (Liang and Pardee, 1995, Curr. Opin. Immunol, 7:274-280; McClelland, M. et al., 1995, Trends Genet., 11, 242-246). mRNA from eggs is compared to mRNA from control cells by differential display.
  • RT-PCR products are displayed on thin polyacrylamide gels containing 8% urea, the type used for DNA sequencing analysis. Products that are detected in egg cells but absent in control cells are chosen to be analyzed further. Gel purification and sequence analysis of such products can be performed to identify egg plasma membrane polypeptide nucleic acid candidates. Protein-coding sequences of egg plasma membrane polypeptide candidates, i.e., sequences present in egg cells but not in control cells, can be compared to known protein sequences in a data base such as Swiss-prot (Bairoch and Apweiler, 1998, Nucl. Acids Res. 26:38-42; http://www.expasy.ch).
  • Novel sequences can be chosen as potential egg plasma membrane polypeptide candidates. Such gene products can then be isolated from the cDNA population using standard cloning techniques (Ausubel et al, eds., 1992, Current Protocols in Molecular Biology, Greene Publishing Associates and Wiley Interscience, New York), and can be tested for their ability to bind egg plasma membrane polypeptide antibodies.
  • nucleic acid array technology can be used to identify egg plasma membrane protein-specific sequences. Such micro-arrays of cDNA probes have been successfully used to compare the expression patterns of different cell types (DeRisi, et al, 1996, Nat. Genet.14:457-460).
  • Micro-arrays typically have many different DNA molecules fixed at defined "addresses" on a two dimensional, usually glass, support. Each address contains either many copies of a single DNA, or a mixture of different DNA molecules, and each DNA molecule is usually 1000 nucleotides or less in length.
  • the DNAs can be from any source, cDNA libraries, or can be synthesized oligonucleotides. A vast excess of probe is fixed at each address, so that the hybridization signal intensity at that address is limited by the concentration of labeled complementary sequence in immediate proximity to the address.
  • the probe array is useful for measuring the ratio of hybridization
  • mRNA derived from egg plasma membrane polypeptide positive hybrid cells and control cells is
  • sequences of differentially expressed nucleic acids are determined by identifying the addresses where differential hybridization between the two cell populations occurs. These nucleic acid sequences can then be used to identify egg plasma membrane polypeptide gene sequences, to synthesize recombinant protein, and to generate antibodies.
  • cDNAs can be inserted into an appropriate cloning vector, and introduced into an appropriate host organism for propagation. Such cDNA libraries may then be used for preparation of "subtracted" cDNA libraries, or for direct and expression screening for egg plasma membrane polypeptide gene sequences. Methods for such procedures are well known in the art, and are described in standard treatises, e.g. , Methods in Enzymology,
  • 35 A+ mRNA from control cells 35 A+ mRNA from control cells.
  • cDNA molecules expressed only in eggs will not hybridize, and can be removed by passing mixture over a hydroxylapatite column under conditions such that the column specifically retains RNA:DNA duplexes but not DNA or DNA duplexes.
  • the column flow-through containing cDNAs representing mRNAs that are expressed in eggs but not in negative control cells, is cloned into an appropriate vector.
  • biotinylated RNA or cDNA can be used to label negative control cells.
  • the egg specific sequences can be eliminated by passing the hybridization mixture over a streptavidin column.
  • the flow-through can be cloned into an appropriate expression vector.
  • any ofthe above mentioned techniques for subtractive hybridization techniques can be used, or any ofthe other techniques known in the art.
  • the library thus created is plated out to isolate single colonies.
  • this cDNA library contains egg- specific sequences that are absent in negative control cells, the cDNA inserts can simply be sequenced at this point.
  • the colonies can be transferred to nitrocellulose filters.
  • the filters can be incubated with antibody specific to egg plasma membrane polypeptide, and the antibody detected using methods known in the art.
  • the colonies can be transferred to nitrocellulose filters, and incubated, under conditions that promote nucleic acid hybridization, with a nucleic acid probe.
  • a labeled degenerate oligonucleotide can be designed. Protein sequence information is used to design degenerate oligonucleotides containing all possible codons for egg plasma membrane polypeptide amino acids. Sequence information from various regions ofthe protein can be used to generate a series of such degenerate pools of oligonucleotides, where each oligonucleotide pool contains some sequences that are complementary to egg plasma membrane polypeptide gene sequences.
  • Such degenerate oligonucleotide pools can be used to screen the subtracted cDNA library, cDNA inserts can be sequenced, and sequence of positive clones can be used to screen a genomic library and thus identify egg plasma membrane polypeptide genes.
  • the cDNA inserts can be sequenced, and the sequence of positive clones can be used to screen a genomic library and thus identify egg plasma membrane polypeptide gene.
  • the present invention provides various methods for isolation of nucleic acid molecules encoding egg plasma membrane polypeptide by screening cDNA and/or genomic DNA library.
  • a gene library comprises a pool of nucleic acid molecules, in which one or more nucleic acid molecules comprise nucleotide sequences encoding egg plasma membrane polypeptide or a fragment thereof.
  • a gene library can be introduced into the appropriate recombinant cells for replication and screening and for production ofthe proteins encoded by the cDNAs.
  • the invention provides a method for screening a gene library for the egg plasma membrane polypeptide gene using one or more nucleic acid probe, such as a pool of degenerate oligonucleotides having sequences that encode egg plasma membrane polypeptide or a fragment thereof.
  • the nucleic acid sequence ofthe probe can be designed in accordance to available peptide sequence of an egg plasma membrane polypeptide, a fragment or homolog thereof.
  • a probe based on the egg plasma membrane polypeptide peptide sequence of one species can be used to identify and isolate the egg plasma membrane polypeptide gene of a related species.
  • Egg plasma membrane polypeptide can be purified and sequenced. Protein sequence information is then used to design degenerate oligonucleotides containing all possible codons for egg plasma membrane polypeptide amino acids. Sequence information from various regions ofthe protein can be used to generate a series of such degenerate pools of oligonucleotides.
  • each oligonucleotide pool contains some sequences that are complementary in its entirety to egg plasma membrane polypeptide gene sequences.
  • degenerate oligonucleotide pools can be used to screen a gene library, prepared as described herein, supra.
  • the method comprises (a) incubating a labeled nucleic acid probe with DNA molecules derived from recombinant cells containing a plurality of DNA molecules from egg plasma membrane polypeptide positive hybrid cells, for a time period sufficient to allow hybridization ofthe labeled probe to the DNA molecules, wherein the labeled probe having a nucleic acid sequence that comprises a sequence that encodes egg plasma membrane polypeptide or a fragment thereof; (b) identifying the recombinant cell containing the DNA molecule to which the labeled probe bound; (c) recovering the DNA molecule present in the recombinant cell.
  • the invention provides methods for identifying and isolating the egg plasma membrane polypeptide gene that rely on expression of cDNA insert and screening for its activity by binding assays, immunological methods, or an altered cellular phenotype.
  • the egg plasma membrane polypeptide cDNA can be isolated indirectly by screening the cDNA expression library for egg plasma membrane polypeptide activity, such as egg plasma membrane polypeptide antibody-binding activity.
  • egg plasma membrane polypeptide antibodies can be labeled with a detectable compound, such as a radioactive, fluorescent or biotinylated compound, and used as probes to screen bacterial colonies that have been induced to express cDNA inserts.
  • a eukaryotic expression library can be screened by "panning” (Seed, 1987, Proc. Natl. Acad. Sci. USA 84:3365-69). This method is particularly preferred for screening cDNA molecules encoding proteins that are expressed on the cell surface.
  • culture dishes are pre-coated with antibody, which can bind to cells that express egg plasma membrane polypeptide.
  • culture dishes may be coated with an egg plasma membrane polypeptide ligand, which also can bind to cells that express egg plasma membrane polypeptide.
  • Non-adherent cells can be rinsed away, and selected cells can be isolated and their inserts can be further analysed.
  • the type of host cell used in panning is non-adherent to surfaces of cell culture containers, such as plastic, so as to facilitate the screening methods ofthe invention.
  • an SV40 vector and control sequences are utilized, and the resulting cDNA library is introduced into African green monkey cells (COS cells).
  • the cDNA library can be constructed in a vector containing viral control regions, and introduced in mammalian cells by transfection or infection with viral vectors. Cells are distributed on microtiter dishes for screening.
  • the cDNA library can be transiently expressed in mammalian cells.
  • the cDNA used in constructing the library is prepared from mRNA isolated from the egg plasma membrane polypeptide positive hybrid cells ofthe invention.
  • the library is a subtracted cDNA library, wherein gene products common to both egg plasma membrane polypeptide positive hybrid cells and egg plasma membrane polypeptide negative hybrid cells are eliminated from the egg plasma membrane polypeptide positive hybrid cell mRNA or cDNA population by means of subtractive hybridization prior to construction ofthe cDNA library.
  • the library is an cDNA library, or a "subtracted" cDNA library, in which cDNAs common to both egg and sperm, or a somatic cell, are subtracted from egg cDNA population prior to cloning (Fargnoli et al., 1990, Anal. Biochem., 187:364-73; Wang and Brown, 1991, Proc. Natl. Acad. Sci. 88:11505-09; Lisitsyn, 1995, Trends Genet. 11:303-7).
  • An expression construct refers to a polynucleotide comprising egg plasma membrane polypeptide positive hybrid cell derived cDNA sequences operably associated with one or more regulatory regions which enables expression ofthe library of cDNAs in an appropriate host cell. "Operably-associated” refers to an association in which the regulatory regions and the cDNA sequence to be expressed are joined and positioned in such a way as to permit transcription, and ultimately, translation.
  • the regulatory regions necessary for transcription of the cDNA library can be provided by an expression construct.
  • a translation initiation codon (ATG) may also be provided if the cDNA fragments without their cognate initiation codon are to be expressed.
  • RNA polymerase a promoter which is capable of binding RNA polymerase and promoting the transcription of an operably-associated nucleic acid sequence.
  • a promoter is required which is capable of binding RNA polymerase and promoting the transcription of an operably-associated nucleic acid sequence.
  • Such regulatory regions may include those 5 '-non-coding sequences involved with initiation of transcription and translation, such as the TATA box, capping sequence, CAAT sequence, and the like.
  • the non-coding region 3* to the coding sequence may contain transcriptional termination regulatory sequences, such as terminators and polyadenylation sites.
  • Regulatory regions suitable for gene expression are well known in the art (see Section 5.6). Both constitutive and inducible regulatory regions may be used for cDNA expression. It may be desirable to use inducible promoters when the conditions optimal for growth ofthe host cells and the conditions for high level expression ofthe cDNA library are different. This use of an inducible regulatory region may be particularly desirable if some ofthe proteins encoded by the cDNAs confer growth advantages or disadvantage to the recombinant host cells expressing them. Examples of useful regulatory regions are provided in the next section below.
  • the expression constructs comprising the cDNA library operably associated with regulatory regions can be directly introduced into appropriate host cells. See, for example, U.S. Patent No. 5,580,859.
  • the expression constructs can also comprise at both ends specific oligonucleotide sequences, which may be utilized as primers to amplify the cDNAs by polymerase chain reaction (PCR).
  • PCR polymerase chain reaction
  • the design of the primer sequences for DNA amplification and the ligation ofthe primer sequences to the cDNAs can be carried out by any methods known in the art, including those described above employing linkers and adaptors.
  • the amplification can be carried out, e.g., by use of a Perkin-Elmer Cetus thermal cycler and Taq polymerase (Gene Amp TM ).
  • Such a library of cDNA expression constructs can be amplified and maintained in vitro, without the use of DNA sequences that propagate the polynucleotide within living cells. Depending on needs, an aliquot ofthe cDNA expression library can be thawed and introduced directly into host cells. Such expression constructs can be used for expression of cDNAs transiently in recombinant host cells.
  • An expression vector is a cloning vector that can be used for maintenance and expression of cDNA library in an appropriate host cell. Any cloning vector known in the art can be used to propagate the cDNA library.
  • a variety of cloning vectors may be used in the present invention which include, but are not limited to, plasmids, cosmids, phage, phagemids, or modified viruses.
  • such cloning vectors comprise a functional origin of replication for propagation ofthe vector in an appropriate host cell, one or more restriction endonuclease sites for insertion ofthe cDNA library, and one or more selection markers.
  • the cloning vector must be used with a compatible host cell which may be derived from a prokaryotic or an eukaryotic organism including but not limited to bacteria, yeasts, insects, mammals, and humans.
  • Host cells broadly encompass cells of unicellular organisms, such as bacteria, fungi, and yeast, and of multicellular organisms, such as insects and animals including but not limited to birds, mammals and humans. Host cells may be obtained from private laboratory deposits, public culture collections such as the American Type Culture Collection, or from commercial suppliers.
  • cDNA expression cloning in a eukaryotic host is advantageous because egg plasma membrane polypeptide(s) can be post-translationally modified and correctly inserted into the plasma membrane. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of cDNA-encoded proteins may enhance egg plasma membrane polypeptide activity.
  • a eukaryotic host-vector system is preferred, a mammalian host- vector system is more preferred, and a human host- vector system is the most preferred.
  • Preferred mammalian host cells include but are not limited to those derived from humans, monkeys and rodents, such as Chinese hamster ovary (CHO) cells, NIH/3T3, COS, HeLa, Daudi, 293, 293-EBNA, VERO, etc. (see, for example, Kriegler M. in "Gene Transfer and Expression: A Laboratory Manual", New York, Freeman & Co. 1990).
  • any ofthe cloning and expression vectors described herein may be synthesized and assembled from known DNA sequences by well known techniques in the art.
  • the regulatory regions and enhancer elements can be of a variety of origins, both natural and synthetic. Some vectors and host cells may be obtained commercially.
  • Non- limiting examples of useful vectors are pCDM8, ⁇ DR2 (see Ausubel et al, eds., 1988, Current Protocols in Molecular Biology, Greene Publishing Associates and Wiley
  • an exemplary expression host-vector system is ⁇ DR2 which is a lambda bacteriophage-based cloning vector coupled with a mammalian expression plasmid.
  • Advantages of this system include the utilization of highly efficient lambda in vitro packaging systems for initially generating a library in E. coli hosts. Size selection may not be required since the packaging system only accepts inserts in a certain size range. Lambda vectors generally provide greater ease in amplification and storage.
  • the initial library in E. coli may be amplified to produce supercoiled plasmid DNA which may be used in high efficiency transformation methods for introduction into other expression host organisms.
  • ⁇ DR2 uses the lox P mediated site-specific recombination to excise the expression vector pDR2 containing a cDNA insert from lambda clones which can recircularize to generate a plasmid.
  • the plasmid pDR2 contains eukaryotic regulatory regions based on the Epstein-Barr virus and selection markers that allows direct introduction ofthe cDNA inserts as a library into permissive human host cells at high efficiency.
  • a variety of regulatory regions can be used, for example, the SV40 early and late promoters, the cytomegalovirus (CMV) immediate early promoter, and the Rous sarcoma virus long terminal repeat (RSV- LTR) promoter.
  • Inducible promoters that may be useful in mammalian cells include but are not limited to those associated with the metallothionein II gene, mouse mammary tumor virus glucocorticoid responsive long terminal repeats (MMTV-LTR), ⁇ -interferon gene, and Hsp70 gene (Williams et al, 1989, Cancer Res. 49:2735-42 ; Taylor et al, 1990, Mol.
  • cDNA expression in a host cell may be enhanced by the inclusion of appropriate transcription enhancer elements in the expression vector, such as those found in SV40 virus, Hepatitis B virus, cytomegalovirus, immunoglobulin genes, metallothionein, ⁇ -actin (see Bittner et al, 1987, Methods in Enzymol. 153:516-544; Gorman, 1990, Curr. Op. in Biotechnol. 1:36-47).
  • appropriate transcription enhancer elements such as those found in SV40 virus, Hepatitis B virus, cytomegalovirus, immunoglobulin genes, metallothionein, ⁇ -actin (see Bittner et al, 1987, Methods in Enzymol. 153:516-544; Gorman, 1990, Curr. Op. in Biotechnol. 1:36-47).
  • the expression vector may contain selectable or screenable marker genes for initially isolating, identifying or tracking host cells that contain egg plasma membrane polypeptide cDNA.
  • selectable or screenable marker genes for initially isolating, identifying or tracking host cells that contain egg plasma membrane polypeptide cDNA.
  • a number of selection systems may be used for mammalian cells, including but not limited to the Herpes simplex virus thymidine kinase (Wigler et al, 1977, Cell 11 :223), hypoxanthine-guanine phosphoribosyltransferase (Szybalski and Szybalski, 1962, Proc. Natl. Acad. Sci.
  • adenine phosphoribosyltransferase (Lowy et al, 1980, Cell 22:817) genes can be employed in tk “ , hgprt " or aprt " cells, respectively.
  • antimetabolite resistance can be used as the basis of selection for dihydrofolate reductase (dhfr), which confers resistance to methotrexate (Wigler et al, 1980, Natl. Acad. Sci. USA 77:3567; O'Hare et al, 1981, Proc. Natl. Acad. Sci.
  • a number of viral-based expression systems may also be utilized with mammalian cells to make the cDNA libraries.
  • Vectors using DNA virus backbones have been derived from simian virus 40 (SV40) (Hamer et al, 1979, Cell 17:725), adenovirus (Van Doren et al, 1984, Mol Cell Biol 4:1653), adeno-associated virus (McLaughlin et al, 1988, J. Virol. 62:1963), and bovine papillomas virus (Zinn et al, 1982, Proc Natl Acad Sci 79:4897).
  • SV40 simian virus 40
  • adenovirus Van Doren et al, 1984, Mol Cell Biol 4:1653
  • adeno-associated virus McLaughlin et al, 1988, J. Virol. 62:1963
  • bovine papillomas virus Zainn et al, 1982, Proc Natl Acad Sci 79
  • the donor DNA sequence may be ligated to an adenovirus transcription translation control complex, e.g., the late promoter and tripartite leader sequence.
  • This chimeric gene may then be inserted in the adenovirus genome by in vitro or in vivo recombination. Insertion in a non-essential region ofthe viral genome (e.g., region El or E3) will result in a recombinant virus that is viable and capable of expressing heterologous products in infected hosts.
  • a non-essential region ofthe viral genome e.g., region El or E3
  • the vaccinia 7.5K promoter may be used (see, e.g., Mackett et al, 1982, Proc. Natl. Acad. Sci. (USA)
  • vectors based on the Epstein-Barr virus (EBV) origin (OriP) and EBV nuclear antigen 1 (EBNA-1; a trans-acting replication factor) can be used.
  • EBV Epstein-Barr virus
  • EBNA-1 EBV nuclear antigen 1
  • Such vectors can be used with a broad range of human host cells, e.g., EBO-pCD (Spickofsky et al, 1990, DNA Prot Eng Tech 2:14-18); pDR2 and ⁇ DR2 (available from Clontech Laboratories).
  • the expression vector pDR2 carries the EBV origin which confers stable episomal maintenance to the vector when activated by EBNA-1. Extremely high transfection efficiencies up to 10 "1 can be obtained when pDR2 is transfected into cell lines which express EBNA-1. Host cells can be rendered proficient for high-efficiency transfections by first transfecting the host cells with an expression construct that produces EBNA-1. cDNA libraries may also be made with a retro virus-based expression cloning system. Retroviruses, such as Moloney murine leukemia virus, can be used since most of the viral gene sequence can be removed and replaced with the cDNA library while the missing viral functions can be supplied in trans.
  • Retroviruses such as Moloney murine leukemia virus
  • retroviruses can efficiently infect and transfer genes to a wide range of cell types including, for example, primary hematopoietic cells.
  • the host range for infection by a retroviral vector can be manipulated by the choice of envelope used for vector packaging.
  • a retroviral vector can comprise a 5' long terminal repeat (LTR), a 3' LTR, a packaging signal, a bacterial origin of replication, and a selectable marker.
  • the cDNA is inserted into a position between the 5' LTR and 3' LTR, such that transcription from the 5' LTR promoter transcribes the cloned cDNA.
  • the 5' LTR comprises a promoter, including but not limited to an LTR promoter, an R region, a U5 region and a primer binding site, in that order. Nucleotide sequences of these LTR elements are well known in the art.
  • a heterologous promoter as well as multiple drug selection markers may also be included in the expression vector to facilitate selection of infected cells.
  • yeast a number of vectors containing constitutive or inducible promoters may be used with Saccharomyces cerevisiae (baker's yeast), Schizosaccharomyces pombe (fission yeast), Pichiapastoris, and Hansenula polymorpha (methylotropic yeasts).
  • Saccharomyces cerevisiae bakeer's yeast
  • Schizosaccharomyces pombe Schizosaccharomyces pombe
  • Pichiapastoris methylotropic yeasts
  • Hansenula polymorpha methylotropic yeasts
  • Autographa californica nuclear polyhydrosis virus (AcNPV) a baculovirus
  • AcNPV Autographa californica nuclear polyhydrosis virus
  • the cDNA sequences may be cloned into non-essential regions (for example the polyhedrin gene) ofthe virus and placed under control of an AcNPV promoter (for example the polyhedrin promoter).
  • AcNPV promoter for example the polyhedrin promoter
  • the recombinant host cells may be cultured under standard conditions of temperature, incubation time, optical density, and media composition.
  • Expression constructs containing cloned cDNA can be introduced into the host cell by a variety of techniques known in the art, including but not limited to, for prokaryotic cells, ⁇ -phage packaging and infection, bacterial transformation (Hanahan, 1985, in DNA Cloning, A Practical Approach, 1:109-136), and for eukaryotic cells, calcium phosphate mediated transfection (Wigler et al, 1977, Cell 11:223-232), liposome-mediated transfection (Schaefer-Ridder et al, 1982, Science 215:166-168), electroporation (Wolff et al, 1987, Proc. Natl. Acad. Sci. 84:3344), and microinjection (Cappechi, 1980, Cell 22:479-488).
  • ovarian-derived cell line may be used. It is preferable that the type of host cell is non-adherent to surfaces of cell culture containers, such as plastic, so as to facilitate screening methods and harvesting ofthe cells.
  • an SV40 vector and control sequences are utilized, and the resulting cDNA library is introduced into African green monkey cells (COS cells).
  • the cDNA library can be constructed in a vector containing viral control regions, and introduced in mammalian cells by transfection or infection with viral vectors. Cells are distributed on microtiter dishes for screening.
  • the cDNA library can be transiently expressed in mammalian cells.
  • the cDNA used in constructing the library is prepared from mRNA isolated from the egg plasma membrane polypeptide positive hybrid cells ofthe invention.
  • the library is a "subtracted" cDNA library, wherein gene products common to both egg plasma membrane polypeptide positive hybrid cells and egg plasma membrane polypeptide negative hybrid cells are eliminated from the egg plasma membrane polypeptide positive hybrid cell mRNA or cDNA population by means of subtractive hybridization prior to construction ofthe cDNA library (see Section 5.4.4).
  • the library is a ovarian cell cDNA library, or a subtracted ovarian cell library (Fargnoli et al, 1990, Anal. Biochem., 187:364-73; Wang and Brown, 1991, Proc. Natl. Acad. Sci. 88:11505-09; Lisitsyn, 1995, Trends Genet.
  • the cDNA library can be screened directly or indirectly. A number of indirect methods are possible that rely on expression of cDNA insert and screening for its activity by binding assays, immunological methods, or an altered cellular phenotype.
  • egg plasma membrane polypeptide can be isolated indirectly by screening the cDNA expression library for egg plasma membrane polypeptide activity, such as ligand binding or egg plasma membrane polypeptide antibody-binding activity.
  • egg plasma membrane polypeptide antibodies can be labeled with a detectable compound, such as a radioactive, fluorescent or biotinylated compound, and used as probes to screen bacterial colonies that have been induced to express cDNA inserts.
  • the eukaryotic expression library can be screened by panning (Seed, 1987, Proc. Natl. Acad. Sci. USA 84:3365-69). Using this technique, culture dishes are pre-coated with antibody, which can bind to cells that express egg plasma membrane polypeptide. Alternatively, culture dishes may be coated with egg plasma membrane polypeptide protein, which also can bind to cells that express egg plasma membrane polypeptide. Non-adherent cells can be rinsed away, and selected cells can be isolated and their inserts can be further analyzed. Alternatively, a cDNA library can be screened directly by hybridization. An oligonucleotide probe designed from the sequence ofthe egg plasma membrane polypeptide protein. Egg plasma membrane polypeptide(s)
  • each oligonucleotide pool contains some sequences that are
  • oligonucleotide pools can be used to screen a cDNA library, prepared as described herein, supra.
  • the expression library can be screened with fluorescently or magnetically labeled egg plasma membrane polypeptide antibody, using
  • cDNA can be cloned into a plasmid or phage vector.
  • Vectors based on E. coli are the most popular and versatile systems for high level expression of foreign proteins (Makrides, 1996, Microbiol. Rev.,
  • Non-limiting examples of regulatory regions that can be used for expression in E. coli may include but not limited to lac, trp, lpp, phoA, recA, tac, T3, T7 and ⁇ P L (Makrides, 1996, Microbiol Rev, 60:512-538).
  • Non-limiting examples of prokaryotic expression vectors may include the ⁇ gt vector series such as ⁇ gtl 1 (Huynh et al, 1984 in "DNA Cloning Techniques", Vol. I: A Practical Approach (D. Glover, ed.), pp. 49-78, IRL
  • ⁇ gtl 1 is particularly advantageous for this purpose.
  • the phage contains the temperature sensitive repressor ⁇ cl857 which is inactive at 42°C and the expression ofthe cDNA insert is under the control ofthe lac operon (Young and Davis, 1983, Science 222:778-782). Proteins may be induced by shifting temperature to 42 °C. In this way, the
  • Expression constructs containing cloned cDNA can be introduced into the prokaryotic host cell by a variety of techniques known in the art, including but not limited to, ⁇ -phage packaging and infection, transduction and transformation (Hanahan, 1985, in DNA Cloning, A Practical Approach, 1 : 109- 136). Bacteria is infected with phage or transformed with plasmid carrying the cDNA library, plated on LB agar plates, and induced to express cDNA inserts.
  • a potential drawback of a prokaryotic host-vector system is the inability to perform many ofthe post-translational processing, folding and insertion into membranes normally required of cell surface receptors.
  • a specific cDNA insert can be detected and isolated by inducing expression ofthe cDNA inserts and utilizing screening methods that rely on detection of protein activity. Such methods include filter binding to a labeled ligand or immunological methods to detect antibody binding.
  • egg surface polypeptide can be isolated by screening the cDNA expression library for egg surface polypeptide activity, such as egg surface polypeptide antibody-binding or ligand binding.
  • egg surface polypeptide antibodies can be labeled with a detectable compound, such as a radioactive, fluorescent or biotinylated compound can be used as probes to screen induced proteins colonies attached to filters.
  • a detectable compound such as a radioactive, fluorescent or biotinylated compound can be used as probes to screen induced proteins colonies attached to filters.
  • Egg surface polypeptide antibody mixture is incubated using conditions that promote binding and developed as described above to detect egg surface polypeptide clones.
  • immunological methods are used to detect antibody.
  • a cDNA library can be screened for egg surface polypeptide expression in frog oocytes.
  • Frog oocytes are advantageous for this purpose because their large size and (1-1.2 mm) and their abundance of protein translation machinery.
  • insertion of receptor proteins can be inserted into membranes readily screened for activity.
  • a cDNA library is constructed in a vector containing T3, T7, SP6 or other RNA polymerase promoter located on either side of a polylinker containing cloning sites for insertion of cDNA.
  • cDNAs can be prepared and inserted into the vector, the library is amplified, and plasmid DNA is isolated and linearized by cutting with a restriction endonuclease whose site is in the polylinker.
  • Run-off in transcriptions are performed in vitro, by addition of nucleotides and the appropriate polymerase, and mRNAs are injected into oocytes. After allowing for translation, oocytes are incubated with ligand labeled with radioactive, fluorescent, or otherwise detectable compound. Sublibraries displaying a positive signal are further divided, plasmid DNA is isolated, in vitro transcribed and injected until a single clone is isolated. Any ofthe above described methods can be used to identify egg surface polypeptide gene candidates. Positive clones can be isolated, purified and the sequence of their inserts can be determined. Such purified inserts can be used for the isolation of full length and genomic sequences, and for the expression of egg surface polypeptide proteins as described below.
  • nucleotide sequence coding for an egg surface polypeptide protein or a functionally active analog or fragment or other derivative thereof can be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for the transcription and translation ofthe inserted protein-coding sequence.
  • the necessary transcriptional and translational signals can also be supplied by the native egg surface polypeptide gene and/or its flanking regions.
  • host- vector systems can be utilized to express the protein-coding sequence.
  • mammalian cell systems infected with virus e.g., vaccinia virus, adenovirus, etc.
  • insect cell systems infected with virus e.g., baculovirus
  • microorganisms such as yeast containing yeast vectors, or bacteria transformed with bacteriophage, DNA, plasmid DNA, or cosmid DNA.
  • the expression elements of vectors vary in their strengths and specificities. Depending on the host- vector system utilized, any one of a number of suitable transcription and translation elements can be used.
  • a fragment of an egg surface polypeptide protein comprising one or more domains ofthe egg surface polypeptide protein is expressed.
  • any ofthe methods previously described for the insertion of DNA fragments into a vector can be used to construct expression vectors containing a chimeric gene comprising of appropriate transcriptional/translational control signals and the protein coding sequences. These methods can include in vitro recombinant DNA and synthetic techniques and in vivo recombinants (genetic recombination). Expression of a nucleic acid sequence encoding an egg surface polypeptide protein or peptide fragment can be regulated by a second nucleic acid sequence so that the egg surface polypeptide protein or peptide is expressed in a host transformed with the recombinant DNA molecule. For example, expression of an egg surface polypeptide protein can be controlled by any promoter/enhancer element known in the art.
  • Promoters which can be used to control egg surface polypeptide gene expression include, but are not limited to, the SV40 early promoter region (Benoist and Chambon, 1981, Nature 290:304-310), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al., 1980, Cell 22:787-797), the herpes thymidine kinase promoter (Wagner et al., 1981, Proc. Natl. Acad. Sci. U.S.A.
  • promoter elements from yeast or other fungi such as the Gal 4 promoter, the ADC (alcohol dehydrogenase) promoter, PGK (phosphoglycerol kinase) promoter, alkaline phosphatase promoter, and the following animal transcriptional control regions, which exhibit tissue specificity and have been utilized in transgenic animals: elastase I gene control region which is active in pancreatic acinar cells (Swift et al., 1984,
  • mouse mammary tumor virus control region which is active in testicular, breast, lymphoid and mast cells (Leder et al., 1986, Cell 45:485-495), albumin gene control region which is active in liver (Pinkert et al., 1987, Genes and Devel. 1 :268-276), alpha- fetoprotein gene control region which is active in liver (Krumlauf et al., 1985, Mol. Cell. Biol. 5:1639- 1648; Hammer et al., 1987, Science 235:53-58; ⁇ l-antitrypsin gene control region which is
  • a vector is used that comprises a promoter operably linked to an egg surface polypeptide gene nucleic acid, one or more origins of replication, and, optionally, one or more selectable markers (e.g., an antibiotic resistance gene).
  • an expression construct is made by subcloning an egg surface polypeptide coding sequence into the EcoRI restriction site of each ofthe three pGEX vectors (glutathione S-transferase expression vectors; Smith and Johnson, 1988, Gene 7:31-40). This allows for the expression ofthe egg surface polypeptide protein product from the subclone in the correct reading frame.
  • Expression vectors containing egg surface polypeptide gene inserts can be identified by three general approaches: (a) nucleic acid hybridization; (b) presence or absence of "marker” gene functions; and (c) expression of inserted sequences.
  • first approach the presence of an egg surface polypeptide gene inserted in an expression vector can be detected by nucleic acid hybridization using probes comprising sequences that are homologous to an inserted egg surface polypeptide gene.
  • second approach the recombinant vector/host system can be identified and selected based upon the presence or absence of certain "marker” gene functions (e.g., thymidine kinase activity, resistance to antibiotics, transformation phenotype, occlusion body formation in baculovirus, etc.
  • recombinants containing the egg surface polypeptide insert can be identified by the absence ofthe marker gene function.
  • recombinant expression vectors can be identified by assaying the egg surface polypeptide product expressed by the recombinant. Such assays can be based, for example, on the physical or functional properties ofthe egg surface polypeptide protein in vitro assay systems, e.g., binding with anti-egg surface polypeptide protein antibody.
  • the expression vectors which can be used include, but are not limited to, the following vectors or their derivatives: human or animal viruses such as vaccinia virus or adenovirus; insect viruses such as baculovirus; yeast vectors; bacteriophage vectors (e.g., lambda phage), and plasmid and cosmid DNA vectors, to name but a few.
  • a host cell strain can be chosen which modulates the expression ofthe inserted sequences, or modifies and processes the gene product in the specific fashion desired. Expression from certain promoters can be elevated in the presence of certain inducers; thus, expression ofthe genetically engineered egg surface polypeptide protein can be controlled.
  • different host cells have characteristic and specific mechanisms for the translational and post-translational processing and modification (e.g. , glycosylation, phosphorylation of proteins. Appropriate cell lines or host systems can be chosen to ensure the desired modification and processing ofthe foreign protein expressed. For example, expression in a bacterial system can be used to produce a non-glycosylated core protein product. Expression in yeast will produce a glycosylated product.
  • the egg surface polypeptide, fragment, analog, or derivative can be expressed as a fusion, or chimeric protein product (comprising the protein, fragment, analog, or derivative joined via a peptide bond to a heterologous protein sequence of a different protein).
  • a chimeric product can be made by ligating the appropriate nucleic acid sequences encoding the desired amino acid sequences to each other by methods known in the art, in the proper coding frame, and expressing the chimeric product by methods commonly known in the art.
  • such a chimeric product can be made by protein synthetic techniques, e.g., by use of a peptide synthesizer (particularly if some protein sequence is available).
  • the recombinant egg surface polypeptide may not be fully functional for a number of reasons.
  • egg surface polypeptide may be modified in vivo.
  • a functional group(s), such as methylation, phosphorylation, or glycosylation, may be added posttranslationally, and play important role(s) in receptor function.
  • egg surface polypeptide may be composed of more than a single polypeptide subunit. In this case recombinant egg surface polypeptide will lack the full activity ofthe native protein.
  • an egg surface protein may be used as an immunogen to generate antibodies which immunospecifically bind such an immunogen.
  • Such antibodies include but are not limited to polyclonal, monoclonal, chimeric, single chain, Fab fragments, and an Fab expression library.
  • antibodies to a human egg surface protein are produced.
  • antibodies to a domain e.g., the extracelluar domain released by treatment with PI-PLC
  • fragments of an egg surface protein identified as hydrophilic are used as immunogens for antibody production.
  • polyclonal antibodies to an egg surface protein or derivative or analog thereof may be obtained.
  • various host animals including but not limited to rabbits, mice, rats, etc can be immunized by injection with the native egg surface proteins, or a synthetic version, or derivative (e.g., fragment) thereof.
  • adjuvants may be used to increase the immunological response, depending on the host species, and including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and corynebacterium parvum.
  • BCG Bacille Calmette-Guerin
  • any technique which provides for the production of antibody molecules by continuous cell lines in culture may be used.
  • the hybridoma technique originally developed by Kohler and Milstein (1975, Nature 256:495- 497), as well as the trioma technique, the human B-cell hybridoma technique (Kozbor et al., 1983, Immunology Today 4:72), and the EBV-hybridoma technique to produce human monoclonal antibodies Colde et al., 1985, in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96).
  • monoclonal antibodies can be produced in germ-free animals utilizing recent technology (PCT/US90/02545).
  • human antibodies may be used and can be obtained by using human hybridomas (Cote et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:2026-2030) or by transforming human B cells with EBV virus in vitro (Cole et al., 1985, in Monoclonal Antibodies and Cancer Therapy. Alan R. Liss, pp. 77-96).
  • techniques developed for the production of "chimeric antibodies” (Morrison et al., 1984, Proc. Natl. Acad. Sci.
  • Antibody fragments which contain the idiotype ofthe molecule can be generated by known techniques.
  • such fragments include but are not limited to: the F(ab') 2 fragment which can be produced by pepsin digestion ofthe antibody molecule; the Fab' fragments which can be generated by reducing the disulfide bridges ofthe F(ab') 2 fragment, the Fab fragments which can be generated by treating the antibody molecule with papain and a reducing agent, and Fv fragments.
  • screening for the desired antibody can be accomplished by techniques known in the art, e.g. ELISA (enzyme-linked immunosorbent assay).
  • ELISA enzyme-linked immunosorbent assay
  • an antibody that specifically binds a first egg surface protein homolog but which does not specifically bind a different egg surface protein homolog one can select on the basis of positive binding to the first egg surface protein homolog and a lack of binding to the second egg surface protein homolog.
  • Antibodies specific to a domain of an egg surface proteins are also provided.
  • the foregoing antibodies can be used in methods known in the art relating to the localization and activity ofthe egg surface proteins ofthe invention, e.g., for imaging these proteins, measuring levels thereof in appropriate physiological samples, in diagnostic methods, etc.
  • anti-egg surface antibodies and fragments thereof containing the extracellular domain are useful contraceptive vaccines.
  • the egg surface proteins ofthe invention are involved in mediating sperm- egg fusion via a direct interaction between egg surface proteins and a sperm ligand.
  • the present invention relates to in vitro and in vivo assay systems, described in the subsections below, which can be used to identify compounds or compositions that modulate the activity of egg surface polypeptide and its interaction with a sperm ligand.
  • Such molecules such as peptides or non-protein molecules, including organic or inorganic small molecules, large molecules, antibodies, and nucleotide sequences may bind egg surface polypeptide with differing affinities.
  • Such molecules can serve as powerful modulators of fertilization in vivo, and can be used therapeutically to modulate the fertility.
  • the screening assays ofthe present invention may also be used to identify compounds or compositions that modulate the interaction of egg surface polypeptides with its binding partners, as identified herein.
  • Methods to screen potential agents for their ability to disrupt or moderate egg surface polypeptide expression and activity can be designed based on the Inventor's discovery of egg surface polypeptides, such as M70, M35/45, H25/40, and GPI-linked ZP3, and their role in egg-sperm fusion and fertilization.
  • the egg surface polypeptide proteins, nucleic acids, and derivatives can be used in screening assays to detect molecules that specifically bind to egg surface polypeptide proteins, derivatives, or nucleic acids, and thus have potential use as agonists or antagonists of egg surface polypeptide, to modulate fertility.
  • such assays are performed to screen for molecules with potential utility in modulating fertility, thereby useful as contraceptive or sterilization agents.
  • recombinant cells expressing egg surface polypeptide nucleic acids can be used to recombinantly produce an egg surface polypeptide in these assays, to screen for molecules that bind to the egg surface polypeptide. Similar methods can be used to screen for molecules that bind to egg surface polypeptide derivatives or nucleic acids. Methods that can be used to carry out the foregoing are commonly known in the art.
  • the screening assays can be used to identify compounds and compositions including peptides and organic, non-protein molecules that modulate egg surface polypeptide activity.
  • Recombinant, synthetic, and otherwise exogenous compounds may have binding capacity and, therefore, may be candidates for pharmaceutical agents.
  • the proteins and compounds include endogenous cellular components which interact with the identified genes and proteins in vivo. Such endogenous components may provide new targets for pharmaceutical and therapeutic interventions.
  • any of a variety of exogenous compounds may be screened for binding capacity.
  • exogenous compounds both naturally occurring and/or synthetic (e.g., libraries of small molecules or peptides)
  • libraries of small molecules or peptides may be screened for binding capacity.
  • both naturally occurring and/or synthetic compounds may be screened for modulating egg surface polypeptide activity.
  • cell lysates or tissue homogenates may be screened for proteins or other compounds which bind to one ofthe normal or mutant egg surface polypeptide genes and the egg surface polypeptide proteins.
  • in vitro selection methods several types of method are likely to be particularly convenient and/or useful for screening test agents.
  • the assays ofthe present invention may be first optimized on a small scale (i.e., in test tubes), and then scaled up for high-throughput assays.
  • the screening assays of the present may be performed in vitro, i.e.
  • test compounds which are shown to modulate the activity of egg surface polypeptide in vitro, as described herein will further be assayed in vivo in cultured cells and animal models to determine if the test compound has the similar effects in vivo and to determine the effects ofthe test compound on T-cell cytotoxicity, antigen presentation, tumor progression, the accumulation or degradation of positive and negative regulators, cellular proliferation, etc.
  • kits cells expressing egg surface polypeptide or cell lysates thereof can be packaged in a variety of containers, e.g., vials, tubes, microtiter well plates, bottles, and the like. Other reagents can be included in separate containers and provided with the kit; e.g., positive control samples, negative control samples, buffers, cell culture media, etc.
  • peptide libraries may be used to screen for agonists or antagonists of egg surface polypeptide.
  • Diversity libraries such as random or combinatorial peptide or non-peptide libraries can be screened for molecules that specifically bind to egg surface polypeptide.
  • Many libraries are known in the art that can be used, e.g., chemically synthesized libraries, recombinant (e.g., phage display libraries), and in vitro translation-based libraries.
  • phage display libraries are described in Scott and Smith, 1990, Science 249:386-390; Devlin et al., 1990, Science, 249:404-406; Christian, et al., 1992, J. Mol. Biol. 227:711-718; Lenstra, 1992, J. Immunol. Meth. 152:149-157; Kay et al., 1993, Gene 128:59-65; and PCT Publication No. WO 94/18318 dated August 18, 1994.
  • a benzodiazepine library (see e.g., Bunin et al., 1994, Proc. Natl. Acad. Sci. USA 91:4708-4712) can be adapted for use.
  • Peptoid libraries (Simon et al., 1992, Proc. Natl. Acad. Sci. USA 89:9367-9371) can also be used.
  • Another example of a library that can be used, in which the amide functionalities in peptides have been permethylated to generate a chemically transformed combinatorial library, is described by Ostresh et al. (1994, Proc. Natl. Acad. Sci. USA 91:11138-11142).
  • Screening the libraries can be accomplished by any of a variety of commonly known methods. See, e.g., the following references, which disclose screening of peptide libraries: Parmley and Smith, 1989, Adv. Exp. Med. Biol. 251 :215-218; Scott and Smith, 1990, Science 249:386-390; Fowlkes et al., 1992; BioTechniques 13:422-427; Oldenburg et al., 1992, Proc. Natl. Acad. Sci.
  • screening can be carried out by contacting the library members with egg surface polypeptide protein (or nucleic acid or derivative) immobilized on a solid phase surface and harvesting those library members that bind to the protein (or nucleic acid or derivative).
  • a library can be screened by passing phage from a continuous phage display library through a column containing purified egg surface polypeptide linked to a solid phase surface, such as plastic beads. By altering the stringency ofthe washing buffer, it is possible to enrich for phage that express peptides with high affinity for egg surface polypeptide. Phage isolated from the column can be cloned and the affinities ofthe short peptides can be measured directly.
  • Sequences for more than one oligonucleotide can be combined to test for even higher affinity binding to egg surface polypeptide. Knowing which amino acid sequences confer the strongest binding to egg surface polypeptide, computer models can be used to identify the molecular contacts between egg surface polypeptide and ligand. This will allow the design of non- protein compounds which mimic those contacts. Such a compound may have the same activity ofthe peptide and can be used therapeutically, having the advantage of being efficient and less costly to produce.
  • the solid support is egg surface polypeptide protein (or nucleic acid or derivative) immobilized on a microtiter dish.
  • Cells that express library members are cultivated under conditions that allow expression of the library members in the microtiter dish.
  • Library members that bind to the protein (or nucleic acid or derivative) are harvested.
  • Such methods are described by way of example in Parmley and Smith, 1988, Gene 73:305-318; Fowlkes et al., 1992, BioTechniques 13:422-427; PCT Publication No. WO 94/18318; and in references cited hereinabove.
  • interactions between egg surface polypeptide and a test compound may be assayed in vitro.
  • Known or unknown molecules are assayed for specific binding to egg surface polypeptide nucleic acids, proteins, or derivatives under conditions conducive to binding, and then molecules that specifically bind to egg surface polypeptide are identified.
  • the two components can be measured in a variety of ways.
  • One approach is to label one ofthe components with an easily detectable label, place it together with a test component(s) under conditions that allow binding to occur, perform a separation step which separates bound labeled component from unbound labeled component, and then measure the amount of bound component.
  • egg surface polypeptide can be labeled and added to a test agent, using conditions that allow binding to occur.
  • Binding ofthe test agent can be determined using polyacrylamide gel analysis to compare complexes formed in the presence and absence of the test agent.
  • the screening may be performed by adding the labeled egg surface polypeptide to in vitro translation systems such as a rabbit reticulocyte lysate (RRL) system and then proceeding with the binding reaction.
  • in vitro translation-based libraries include but are not limited to those described in PCT Publication No. WO 91/05058 dated April 18, 1991; and Mattheakis et al, 1994, Proc. Natl. Acad. Sci. USA 91:9022-9026.
  • binding of egg surface polypeptide to a test agent may be assayed in intact cells in culture or in animal models in the presence and absence of the test compound.
  • a labeled test agent may be mixed with eggs in culture, or to crude extracts obtained from animal tissue samples, and the test compound may be added. Binding can be assayed using microscopy or confocal microscopy, for example.
  • the test agent may be assayed in intact cells in animal models. A labeled test agent may be administered directly to an animal. The uptake ofthe test agent may be measured.
  • host cells to which the test compound is added may be genetically engineered to express egg surface polypeptide and its target interactor (such as an egg surface polypeptide antibody or an egg surface polypeptide ligand) which may be transient, induced or constitutive, or stable.
  • target interactor such as an egg surface polypeptide antibody or an egg surface polypeptide ligand
  • a wide variety of host cells may be used including, but not limited to, tissue culture cells, mammalian cells, yeast cells, and bacteria. Each cell type has its own set of advantages and drawbacks.
  • Mammalian cells, such as egg cells which express the egg surface polypeptides ofthe invention may be a preferred cell type in which to carry out the assays ofthe present invention. Bacteria and yeast are relatively easy to cultivate but process proteins differently from mammalian cells.
  • the invention provides for a method for detecting the interaction between egg surface polypeptide and a known potential ligand, such as a sperm integrin.
  • a known potential ligand such as a sperm integrin.
  • Insect cells can be infected with baculoviruses co-expressing egg surface polypeptide and the known sperm integrin, and cell extracts can be prepared and analyzed for protein-protein interactions. Protein-protein interactions can be analyzed by methods known in the art, such as Western blotting or immune precipitation using egg surface polypeptide specific antibodies together with an anti-integrin antibody, and analyzing complexes by polyacrylamide gel electrophoresis.
  • the invention further provides methods for screening cells having egg surface polypeptide proteins (or fragments thereof) as one of their cell surface membrane components for known cell surface molecules as potential ligands.
  • cells engineered to express egg surface polypeptide nucleic acids can be used to recombinantly produce egg surface polypeptide proteins either wild-type or dominant negative mutants in cells that also express a putative egg surface polypeptide binding partner molecule.
  • Potential candidates for an egg surface polypeptide binding partner include, but are not limited to, such known substrates as sperm integrin. Extracts can also be used to test whether the presence of egg surface polypeptide increases or decreases the level ofthe potential binding partner.
  • the two-hybrid system for selecting interacting proteins or peptides in yeast can be used to identify molecules that specifically bind to egg surface polypeptide protein or derivative.
  • peptide libraries may be used to identify for unknown potential ligands of egg surface polypeptide.
  • Diversity libraries such as random or combinatorial peptide libraries can be screened for molecules that specifically bind to egg surface polypeptide.
  • Many libraries are known in the art that can be used, e.g., chemically synthesized libraries, recombinant (e.g., phage display libraries), and in vitro translation-based libraries.
  • a substrate or interacting protein Once a substrate or interacting protein is identified, then one can assay for modulators ofthe egg surface polypeptide interaction with such a protein.
  • the present invention provides for methods of detecting agonists and antagonists of such interactions.
  • Recombinant egg surface polypeptide and putative agonist or antagonist molecules can be incubated together, under conditions that allow binding to occur, such as 37°C for 30 minutes. Protein-protein complex formation can be detected by acrylamide gel analysis, by methods known in the art. This assay can be used to identify modulators of interactions of sperm and egg surface proteins involved in fertilization.
  • Purified or partially purified components which have been determined to interact with one another by the methods described above can be placed under conditions in which the interaction between them would normally occur, with and without the addition of the test agent, and the procedures previously established to analyze the interaction can be used to assess the impact ofthe test agent.
  • the purified or partially purified components may be prepared by fractionation of extracts of eggs, or they may be obtained by expression of cloned genes or cDNAs or fragments thereof, optionally followed by purification ofthe expressed material.
  • Mouse or hamster egg surface proteins can be used in any of a variety of vaccines in human and non-human animals.
  • the present invention encompasses vaccines useful for contraception.
  • egg surface polypeptides involved in sperm-egg fusion such as M70, M35/45, H25/40, and GPI-linked ZP3, are delivered to a subject to elicit an active immune response.
  • the vaccine acts as a temporary and reversible antagonist ofthe function ofthe egg surface proteins ofthe invention.
  • such vaccines could be used for active immunization of a subject, to raise an antibody response to temporarily block the sperm's access to the egg plasma antigen.
  • an antigen could be administered at a certain period ofthe month, for example during ovulation of a female subject to block fertilization.
  • egg surface polypeptides involved in sperm-egg fusion are useful as vaccines for permanent sterilization of a subject.
  • Such vaccines can be used to elicit a T-cell mediated attack on the eggs, having an othoritic effect, useful as a method for irreversible sterilization.
  • Methods for generating T-cell specific responses, such as adoptive immunotherapy are well known in the art (see, for example, Vaccine Design, Michael F. Powell and Mark J. Newman Eds., Plenum Press, New York, 1995, pp 847-867). Such techniques may be particular useful for vetinary contraceptive or sterilization purposes, 5 where a single dose vaccination may be desirable.
  • Egg surface protein antigens can be produced in large amounts and purified for use in vaccine preparations.
  • the egg surface proteins ofthe invention also have utility ⁇ in immunoassays, e ⁇ g., to detect or measure in a sample of body fluid from a vaccinated subject the presence of antibodies to the antigen, and thus to diagnose and/or to monitor immune response ofthe subject subsequent to vaccination.
  • the immunopotency of egg surface protein antigens can be determined by monitoring the immune response in test animals following immunization with the egg 0 surface protein antigen, or by use of any immunoassay known in the art. Generation of a humoral (antibody) response and/or cell-mediated immunity, may be taken as an indication of an immune response.
  • Test animals may include mice, hamsters, dogs, cats, monkeys, rabbits, chimpanzees, etc., and eventually human subjects.
  • Methods of introducing the vaccine may include oral, intravaginal, 5 intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, and via scarification (scratching through the top layers of skin, e.g., using a bifurcated needle) or any other standard routes of immunization.
  • the immune response ofthe test subjects can be analyzed by various approaches such as: the reactivity ofthe resultant immune serum to the egg protein antigen, as assayed by known techniques, e.g., immunosorbent assay 0 (ELISA), immunoblots, radioimmunoprecipitations, etc., or in the case where the egg protein antigen displays antigenicity or immunogenicity, by protection ofthe immunized host against fertilization in the immunized host.
  • ELISA immunosorbent assay 0
  • the vaccine ofthe invention may be tested in rabbits for the ability to induce an antibody 5 response to the egg surface protein antigen.
  • Male specific-pathogen-free (SPF) young adult New Zealand White rabbits may be used.
  • the test group each receives a fixed concentration ofthe vaccine.
  • a control group receives an injection of 1 mM Tris-HCl pH 9.0 without the egg surface protein antigen.
  • Blood samples may be drawn from the rabbits every one or two weeks, and serum analyzed for antibodies to the egg surface protein.
  • the presence of antibodies specific for the antigen may be assayed, e.g., using an ELISA.
  • Suitable preparations of such vaccines include injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, suspension in, liquid prior to injection, may also be prepared.
  • the preparation may also be emulsified, or the polypeptides encapsulated in liposomes.
  • the active immunogenic ingredients are often mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients are, for example, water saline, dextrose, glycerol, ethanol, or the like and combinations thereof.
  • the vaccine preparation may also include minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and/or adjuvants which enhance the effectiveness ofthe vaccine.
  • adjuvants which may be effective, include, but are not limited to: aluminum hydroxide, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N- acetyl-nor-muramyl-L-alanyl-D-isoglutamine, N-acetylmuramyl-L-alanyl-D-isoglutaminyl- L-alanine-2-( -2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine.
  • thr-MDP N-acetyl-muramyl-L-threonyl-D-isoglutamine
  • thr-MDP N- acetyl-nor-muramyl-L-alanyl-D-isoglutamine
  • the effectiveness of an adjuvant may be determined by measuring the induction of antibodies directed against an immunogenic polypeptide containing an egg surface protein polypeptide epitope, the antibodies resulting from administration of this polypeptide in vaccines which are also comprised ofthe various adjuvants.
  • the polypeptides may be formulated into the vaccine as neutral or salt forms.
  • Pharmaceutically acceptable salts include the acid addition salts (formed with free amino groups ofthe peptide) and which are formed with inorganic acids, such as, for example, hydrochloric or phosphoric acids, or organic acids such as acetic, oxalic, tartaric, maleic, and the like. Salts formed with free carboxyl groups may also be derived from inorganic bases, such as, for example, sodium potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine and the like.
  • the vaccines ofthe invention may be multivalent or univalent. Multivalent vaccines are made from recombinant viruses that direct the expression of more than one antigen.
  • the patient to which the vaccine is administered is preferably a mammal, most preferably a human, but can also be a non-human animal including but not limited to cows, horses, sheep, pigs, fowl (e.g., chickens), goats, cats, dogs, hamsters, mice and rats.
  • the vaccine formulations ofthe invention comprise an effective immunizing amount ofthe egg surface protein and a pharmaceutically acceptable carrier or excipient.
  • Vaccine preparations comprise an effective immunizing amount of one or more antigens and a pharmaceutically acceptable carrier or excipient.
  • Pharmaceutically acceptable carriers include but are not limited to saline, buffered saline, dextrose, water, glycerol, sterile isotonic aqueous buffer, and combinations thereof.
  • a physiologically balanced culture medium containing one or more stabilizing agents such as stabilized, hydrolyzed proteins, lactose, etc.
  • the carrier is preferably sterile. The formulation should suit the mode of administration.
  • composition if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.
  • the composition can be a liquid solution, suspension, emulsion, tablet, pill, capsule, sustained release formulation, or powder.
  • Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc.
  • the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent.
  • a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent.
  • an ampoule of sterile diluent can be provided so that the ingredients may be mixed prior to administration.
  • a lyophilized egg surface protein polypeptide of the invention is provided in a first container; a second container comprises diluent comprising an aqueous solution of 50% glycerin, 0.25% phenol, and an antiseptic (e.g., 0.005% brilliant green).
  • diluent comprising an aqueous solution of 50% glycerin, 0.25% phenol, and an antiseptic (e.g., 0.005% brilliant green).
  • An effective immunizing amount is that amount sufficient to produce an immune response to the antigen in the host to which the vaccine preparation is administered.
  • purified antigens as vaccine preparations can be carried out by standard methods.
  • the purified protein(s) should be adjusted to an appropriate concentration, formulated with any suitable vaccine adjuvant and packaged for use.
  • suitable adjuvants may include, but are not limited to: mineral gels, e.g., aluminum hydroxide; surface active substances such as lysolecithin, pluronic polyols; polyanions; peptides; oil emulsions; alum, and MDP.
  • the immunogen may also be incorporated into liposomes, or conjugated to polysaccharides and/or other polymers for use in a vaccine formulation.
  • the recombinant antigen is a hapten, i.e., a molecule that is antigenic in that it can react selectively with cognate antibodies, but not immunogenic in that it cannot elicit an immune response
  • the hapten may be covalently bound to a carrier or immunogenic molecule; for instance, a large protein such as serum albumin will confer immunogenicity to the hapten coupled to it.
  • the hapten-carrier may be formulated for use as a vaccine.
  • Effective doses (immunizing amounts) ofthe vaccines ofthe invention may also be extrapolated from dose-response curves derived from animal model test systems.
  • the invention also provides a pharmaceutical pack or kit comprising one or more containers comprising one or more ofthe ingredients ofthe vaccine formulations of the invention.
  • a pharmaceutical pack or kit comprising one or more containers comprising one or more ofthe ingredients ofthe vaccine formulations of the invention.
  • Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.
  • the present invention thus provides a method of immunizing an animal, comprising administering to the animal an effective immunizing dose of a vaccine ofthe present invention.
  • compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient.
  • the pack may for example comprise metal or plastic foil, such as a blister pack.
  • the pack or dispenser device may be accompanied by instructions for administration.
  • Compositions comprising a compound ofthe invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labelled for treatment of an indicated condition.
  • the antibodies generated against the antigen by immunization with the egg surface proteins ofthe present invention also have potential uses in vaccination against fertilization, sterilization, diagnostic immunoassays, passive immuno therapy, and generation of antiidiotypic antibodies.
  • the generated antibodies may be isolated by standard techniques known in the art (e.g., immunoaffinity chromatography, centrifugation, precipitation, etc.) and used in diagnostic immunoassays.
  • the antibodies may also be used to monitor treatment and/or disease progression.
  • any immunoassay system known in the art may be used for this purpose including but not limited to competitive and noncompetitive assay systems using techniques such as radioimmunoassays, ELISA (enzyme-linked immunosorbent assays), "sandwich” immunoassays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement- fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays and immunoelectrophoresis assays, to name but a few.
  • radioimmunoassays ELISA (enzyme-linked immunosorbent assays), "sandwich” immunoassays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement- fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays and immunoelectrophoresis assay
  • the vaccine formulations ofthe present invention can also be used to produce antibodies for use in passive immunotherapy, in which short-term protection of a host is achieved by the administration of pre-formed antibody directed against a heterologous organism.
  • the antibodies generated by the vaccine formulations ofthe present invention can also be used in the production of antiidiotypic antibody.
  • the antiidiotypic antibody can then in turn be used for immunization, in order to produce a subpopulation of antibodies that bind the initial antigen ofthe pathogenic microorganism (Jerae, 1974, Ann. Immunol. (Paris) 125c:373; Jerne, et al, 1982, EMBO J. 1:234).
  • the amount of immunogen to be used and the immunization schedule will be determined by a physician skilled in the art and will be administered by reference to the immune response and antibody titers ofthe subject.
  • Mouse sperm surface hyaluronidase (also known as PH-20) is GPI- anchored and is thought to aid sperm in passage through the cumulus oopherous and possibly the zona pellucida by hydrolyzing the extracellular matrix protein, hyaluronic acid (Gmachl and Kreil, 1993, Proc. Nat. Acad. Sci. USA 90: 3569-3573; Myles and Primakoff, 1997, Biol. Reprod., 56: 320-327).
  • SAGA-1 is another sperm surface protein which has been shown to be a GPI-linked.
  • PI-PLC phosphatidylinositol-specific phospholipase C
  • the released oolemmal GPI-anchored protein(s) were characterized using two-dimensional (2D) gel electrophoresis and cell surface labeling.
  • PI-PLC Recombinant PI-PLC was isolated from cultured supernatants of Bacillus subtilis (BG2320) transfected with the PI-PLC gene from B. thuringiensis (Henner et al., 1988, Nucl. Acid. Res. 16: 10383-10383). For details on PI-PLC purification see Low et al. (1988, J. Imm. Meth. 113: 101-111).
  • mice gametes for IVF were carried out essentially as described by (Bleil, 1991, Meth. Enz. 225: 253-263). Incubation of mouse gametes was performed in microdrops under paraffin oil at 37°C and 5% CO 2 in Medium 199 (Ml 99, Gibco, Grand Island, NY) supplemented with 4 mg/ml bovine serum albumin (BSA, Sigma, St. Louis, MO) and 3.5 mM sodium pyruvate (Gibco). Epididymides were collected from sacrificed ICR strain retired breeders, placed in 250 ⁇ l medium, minced with watchmaker forceps, and sperm were allowed to swim out from the epididymides for 15 min.
  • BSA bovine serum albumin
  • sperm suspension was then placed under 1.5 ml medium and sperm were allowed to swim up for at least 1 h.
  • Cumulus-oocyte complexes were collected from superovulated ICR strain females in Ml 99. Cumulus cells were removed by treating eggs for 3 min with 1 mg/ml hyaluronidase (Sigma) in M199 and the eggs were then washed in six consecutive 50 ⁇ l drops of M199. Following cumulus cell removal, oocytes were washed by passing the eggs through 50 ⁇ l drops of media covered with mineral oil using a pulled, heat polished, Pasteur pipette (employed in all experiments).
  • Treated sperm were then added to the incubation drops containing treated eggs with a final droplet volume of 100 ⁇ l and a final sperm concentration of lxl 0 6 sperm/ml.
  • PI- PLC was present in the incubation droplet during gamete interaction.
  • the gametes were co-incubated for 1 h, washed gently 3 times in M199, and fixed in PBS containing 4% paraformaldehyde for 1 h.
  • the oocytes were placed in a phosphate buffered saline (PBS)/4% paraformaldehyde solution between a microscope slide and an elevated cover slip.
  • PBS phosphate buffered saline
  • the oocytes were visualized at 200X using a light microscope (Zeiss Axioplan) and a single focal plane for each oocyte was selected in which the widest diameter ofthe zona pellucida could be visualized. The number of bound sperm in that focal plane was then determined.
  • sperm were added to oocytes, the gametes were co-cultured for 2 h, washed 3 times in Ml 99 to remove the PI-PLC and supernumerary sperm and incubated overnight at 37°C and 5% CO 2 .
  • gametes were incubated in 1 ⁇ M Hoechst dye #33342 (Sigma) for 10 min and washed 6 times in M199. The zygotes were then viewed at 200X as described above and zygotes with two blastomeres were scored as fertilized while one-celled oocytes were scored as unfertilized.
  • Fertilization of zona-intact oocytes which had been pre-treated with PI-PLC and washed prior to incubation with untreated sperm Zona-intact oocytes (approximately 20 eggs per group) were treated for 30 min with either lU/ml PI-PLC or lU/ml inactivated PI-PLC in 100 ⁇ l of M199 under oil. The oocytes were then washed through six drops of Ml 99. Untreated sperm were then added to the incubation drops containing treated eggs at a final volume of 100 ⁇ l and sperm concentration of 1X10 6 sperm/ml.
  • the gametes were then co-cultured for 2 h, washed 3 times in Ml 99 and incubated overnight at 37 °C and 5% CO 2 .
  • Zygotes with two blastomeres were scored as fertilized while one-celled oocytes were scored as unfertilized.
  • Zonae pellucida were loosened by treating eggs with Ml 99 containing 10 ⁇ g/ml chymotrypsin (Sigma) for 1 min. The eggs were then washed 6 times in Ml 99 and loosened zonae were removed by mechanical agitation using a pulled Pasteur pipette. The eggs were allowed to recover from chymotrypsin treatment for 4 h in Ml 99. The oocytes (approximately 15 oocytes per group) were then pre-loaded with 1 ⁇ M Hoechst dye #33342 (Sigma) for 10 min and washed 6 times in M199. Swim up sperm were collected and prepared as described in the gamete preparation section and allowed to capacitate for four hours during the oocyte recovery period.
  • swim up sperm (approximately 3X10° sperm/ml) were treated for 30 min with either lU/ml PI-PLC or lU/ml of heat inactivated PI-PLC in 100 ⁇ l of Ml 99 under oil.
  • the sperm were then washed 2 times by centrifugation (five min at 1000 g) in five ml volumes of Ml 99 in 15 ml centrifuge tubes to remove the PI- PLC.
  • the treated sperm were then added to untreated eggs (approximately 15 eggs per group) at a concentration of lxl 0 5 sperm/ml and the gametes were co-incubated for 40 min in 20 ⁇ l drops followed by gentle washing.
  • the eggs were treated with either lU/ml PI-PLC or heat inactivated PI-PLC for 30 min in 50 ⁇ l drops of M199 and washed through six 50 ⁇ l drops of M199 to remove the PI-PLC.
  • the treated eggs were then incubated with untreated sperm (lxl 0 5 sperm/ml) for 40 min in 20 ⁇ l drops containing approximately fifteen oocytes per group followed by gentle washing ofthe eggs in M199.
  • oocytes were treated with either 5U/ml heat inactivated PI-PLC or increasing concentrations of PI-PLC (0-5U), washed, and incubated with untreated sperm as described above.
  • sperm-egg binding and fusion the eggs from each group were then placed in Ml 99 between a microscope slide and an elevated cover slip and visualized at 200X. Binding to the egg was scored by counting the total number of sperm bound per oocyte using phase contrast. Fusion with the egg was scored by counting the number of decondensed sperm heads within each oocyte using fluorescent microscopy.
  • the remaining oocytes were activated by placing the eggs in 0.5 ⁇ M calcium ionophore (A23187, Sigma) for 5 min followed by three washes. The eggs were incubated for 40 min and oocytes were observed as described above. The eggs were considered activated if they had advanced from metaphase II arrest to anaphase II or telophase II (with second polar body).
  • oocytes were placed in acid Tyrodes for 15 sec followed immediately by four washes in M199 (Evans et al, 1997, Dev. Biol. 187:79-93). The eggs were then allowed to recover for 4 h at 37 °C and 5% CO 2 . The eggs were then washed six times in BWW media (Irvine Scientific, Santa Ana, CA) containing 100 ⁇ g/ml polyvinylalcohol (PVA, Sigma), biotinylated with 2 ⁇ g/ml Sulfo-NHS biotin (Pierce, Rockford, IL) in BWW/PVA for 7 min at room temperature, and washed six times in BWW/PVA.
  • BWW media Irvine Scientific, Santa Ana, CA
  • PVA polyvinylalcohol
  • Sulfo-NHS biotin Pierce, Rockford, IL
  • the eggs were then split into two groups of 100 and either mock treated or treated with lU/ml PI-PLC in 20 ⁇ l drops for 30 min.
  • the supernatants were removed, the eggs were washed six times, and the oocytes and the oocyte supernatants were then frozen at -70 °C in BWW/PVA containing protease inhibitors (CompleteTM, Boehringer Mannheim, Mannheim, Germany).
  • the oocytes and supernatants were extracted in Celis lysis buffer containing 2% (v:v) NP-40, 9.8M urea, lOOmM dithiothreitol (DTT), 2% ampholines (pH 3.5-10), and protease inhibitors for 30 min at room temperature (Rasmussen et al, 1991, Electrophoresis 12: 873-882).
  • Isoelectric focusing (IEF) was performed using the Mini- PROTEAN II tube cell (Bio RAD, Richmond, CA) apparatus and protocol with an ampholine mixture (Pharmacia Biotech, Uppsala, Sweden) of pH 3.5-5 (30%), 3.5-10 (40%), 5-7 (20%), and 7-9 (10%).
  • the tube gels were placed on 12 % mini slab gels and the focused proteins were separated in the second dimension at 20 mA per gel.
  • the proteins were then electroblotted to nitrocellulose membranes at 125 mA for 45 min.
  • the nitrocellulose membranes were blocked in PBS with 0.1% Tween and 5% dried milk for 30 min at room temperature, washed 1 time in PBS/0.1% Tween, and probed with 20 ⁇ g/ml strepavidin-HRP (Pierce) for 30 min at room temperature.
  • the blots were washed 3 times 15 min in PBS/0.1% Tween (10 min per wash) and developed using enhanced chemiluminescence (Amersham Corp, Buckinghamshire, U.K.) for 5 min.
  • one unit (l ⁇ g) ofthe PI- PLC preparation was mixed with Celis buffer and separated on a two-dimensional electrophoretic gel as described above and silver stained according to (Hochstrasser et al., 1988, Anal. Biochem. 173: 424-435).
  • mice sperm and eggs were pre-treated separately with either lU/ml heat inactivated PI-PLC or lU/ml PI-PLC for 30 min, and co-cultured in the presence of PI-PLC. Following one hour of co-culture, sperm were observed to bind abundantly to the zona of both control (Fig. 1 A) and treated gametes (Fig. IB). Quantitation revealed no significant difference in the number of sperm-bound per zona pellucida between the control group (43.9 sperm/zona) and the PI-PLC treated group (45.9 sperm/zona) (Fig. IE).
  • sperm and eggs were pre-treated separately with PI-PLC as described above, co-cultured in the presence of PI-PLC for two hours to permit fertilization, washed 3 times to remove the PI-PLC and supernumerary sperm, and incubated overnight.
  • molecular weight of PI-PLC is 30-34 kDa and the zona pellucida is freely permeable to molecules having a mass of less than 170 kDa (Legge, 1995, J. Exp. Zool. 271 : 145-150); therefore the oolemma was likely exposed to PI-PLC during treatment.
  • Oocytes were treated with either 5U/ml of heat inactivated PI-PLC, no PI- PLC, or increasing amounts of PI-PLC (0, 0.05, 0.1, 0.5, 1, 5U/ml), washed, and incubated with untreated sperm to determine if the inhibitory effect of PI-PLC on the oolemma was dose-dependent. Results showed that, as the concentration of PI-PLC was increased, sperm-egg binding and fusion rates decreased in a dose-dependent manner (Fig. 3).
  • the maximal inhibitory effect on sperm-egg binding was reached at 5U/ml while the maximal inhibitory effect on fusion occurred at lU/ml.
  • the recommended dose for releasing most GPI-anchored proteins from intact cells using B. thuringiensis-de ⁇ ved PI-PLC is lU/ml.
  • the dose-dependent inhibition of both sperm-egg binding and fusion by PI-PLC supports the hypothesis that treating oocytes with PI-PLC releases GPI-anchored proteins from the oolemma which are required for fertilization.
  • oocytes were then artificially activated with 0.5 ⁇ m calcium ionophore A23187 for 5 min, washed, and cultured for 40 min. Oocytes which had progressed from metaphase II arrest to anaphase II or telophase were scored as activated. Following culture, there was no observable difference in the number of eggs which resumed meiotic cell division in the control eggs (31 out of 47 oocytes activated, Fig. 5 A) compared with PI-PLC treated eggs (27 out of 44 oocytes activated, Fig. 5B). Treatment of zona-free oocytes with PI-PLC does not effect the ability of beads coated with ⁇ wtt- ⁇ l antibodies to bind to oocytes
  • a bead binding experiment was performed to determine if PI-PLC treatment of zona-free mouse oocytes affected the antibody recognition of a well characterized egg surface integrin. Fluorescent beads were coated with ⁇ 6 ⁇ l antibodies and incubated with either untreated or PI-PLC treated oocytes. No difference was observed in the number of ⁇ l antibody-coated beads bound per oocyte between the control (Fig. 6A) and treatment group (Fig. 6B). Minimal bead binding was observed when beads were coated an with equivalent concentration of an irrelevant antibody and incubated with untreated eggs (Fig. 6C).
  • the supernatants from the treated eggs as well as the egg extracts were separated by 2D electrophoresis, electroblotted to nitrocellulose membranes, probed with strepavidin-HRP, and biotinylated proteins were visualized on radiograms using enhanced chemi-luminescence.
  • the 2D gel repertoire of biotin-labeled egg surface proteins present in the extracts of control eggs is presented in Fig. 7A. Approximately 20 biotin labeled proteins were resolved ranging in molecular weight from approximately 35 to 120 kDA with isoelectric points from 4.5 to 5.5. Following PI- PLC treatment ofthe oocytes (Fig.
  • Fig. 7C a decrease in the presence of the 70 kDa (pi 5) and 35-45 kDa (pi 5.5) protein clusters indicated by arrows in Fig. 7 A was observed in extracts of eggs.
  • the three spots denoted by asterisks in Fig. 7 A represent proteins that bound strepavidin-HRP non-specifically and were detected on 2D blots of oocytes which were not biotinylated.
  • 2D gel analysis of supernatant collected from untreated oocytes following 30 min of incubation showed that no biotinylated egg surface proteins were released into the medium (Fig. 7B).
  • the repertoire of biotin-labeled proteins remaining on the egg surface following PI-PLC treatment is shown in Fig.
  • Acid Tyrodes was used to remove the zona pellucida prior to cell surface biotinylation in the majority ofthe blotting experiments while chymotrypsin was used to de-zonulate oocytes for the sperm-egg binding and fusion assays. To ensure that the method of zona removal did not alter the pattern of labeled egg surface and PI-PLC released proteins, chymotrypisin was also used to de-zonulate oocytes prior to surface labeling and avidin blotting. Other than substituting chymotrypsin to de-zonulate oocytes, all conditions for this experiment were identical to the previous experiment using acid Tyrodes. The repertoire of surface labeled proteins present in the extracts of control eggs is shown in Fig. 8A.
  • PI-PLC releases 70 kDa and 35-45 kDa protein clusters regardless ofthe method of zona removal increasing confidence in the reproducibility of our findings.
  • PLC phospholipase C
  • thuringiensis-de ⁇ ved recombinant PI-PLC is specific for phosphatidylinositol and glycosylated phosphatidylinositol phospholipids (Low et al, 1988, J. Imm. Meth. 113: 101-111) and for this reason was selected for investigating the role of GPI-anchored proteins in sperm-egg interaction in this study.
  • the dose- response curve trial indicated that the maximal effect of PI-PLC on sperm-egg binding and fusion was 1-5 U per ml; which corresponds to that which is recommended for maximal release of GPI-anchored proteins (Dr. Martin Low, personal communication).
  • oocytes which had been treated with PI-PLC could be artificially activated with calcium ionophore, indicating that treated oocytes remained functionally viable.
  • beads coated with ⁇ 6 ⁇ l antibodies could bind to PI-PLC treated eggs in a manner similar to that of controls, thus indicating that non-GPI-linked oolemmal proteins did not appear to be affected by the PI-PLC preparation.
  • both the 70 kDa and the 35-45 kDa protein clusters appear as a series of closely aligned columns having slightly different isoelectric points.
  • Previous literature on 2-D gel protein patterns (Shackelford et al., 1980, J. Exp. Med. 151 : 144-165); (Negm et al., 1991, Comp. Biochem. Phys. Comp. Biochem. 99: 741-749) suggest that these protein clusters represent isoforms of a glycosylated protein. It is not known at this time whether the 70 kDa and 35-45 kDa protein clusters are in fact different proteins or are different isoforms ofthe same protein. While the 70 kDa and 35-45 kDa protein clusters represent candidate mediators of sperm- egg binding and fusion we have no direct evidence as yet they are, in fact, required for fertilization.
  • PI-PLC sensitive proteins The precise function of these PI-PLC sensitive proteins in the fertilization process is unknown at this time.
  • One possibility is that the molecules are involved in the block to polyspermy as is the Ascidian GPI-anchored molecule, N-acetylglucosaminidase (Lambert, 1989, Development 105: 415-420).
  • Ascidians sperm first bind to the ligand, N-acetylglucosamine, on the vitelline coat (VC), then penetrate through the VC and the perivitelline space to reach the egg surface, where sperm-egg fusion then occurs (Rosati and De Santis, 1980, Nature 283: 762-764).
  • Ascidian eggs release N-acetylglucosaminidase from the cell surface into the sea water immediately following fertilization (Lambert, 1989, Development 105: 415-420).
  • the enzyme can also be released by treating Ascidian eggs with exogenous PI-PLC (Lambert and Goode, 1992, Dev. Biol. 154: 95-100).
  • N-acetylglucosaminidase modifies N-acetylgucosamine on the vitelline coat, thus preventing subsequent sperm penetrations.
  • N- acetylglucosaminidase is released from the egg surface by the activity of endogenous phospholipases operating on the extracellular side ofthe surface (Goode et al., 1997, Dev. Growth. Diff. 39: 655-660).
  • N-acetylglucosaminidase is also released from oocytes following fertilization (Miller et al., 1993, J. Cell. Biol. 123: 1431-1401) and subsequently occupies the sperm ⁇ l,4-Galactosyltransferase binding site on the zona pellucida, thus preventing polyspermy.
  • N-acetylglucosaminidase does not appear to be GPI-anchored and has been localized to the cortical granules in mice (Miller et al., 1993, J. Cell. Biol. 123: 1431-1401) and therefore would not be susceptible to PI-PLC treatment.
  • PI-PLC phosphatidylinositol-specific phospholipase C
  • GPI glycosyiphosphatidylinositol
  • PI-PLC Treatment of human sperm with PI-PLC significantly enhanced sperm-egg binding while having no effect on sperm-egg fusion. Treatment of zona-free hamster oocytes with PI-PLC blocked sperm-egg binding and fusion.
  • egg surface proteins were labeled with sulfo-NHS biotin and either mock treated or treated with PI-PLC. Egg protein extracts and egg supernatant proteins from each group were then analyzed by two- dimensional gel electrophoresis followed by avidin blotting.
  • the phosphatidylinositol-specific phospholipase C preparation used for this study was purchased from Boehringer Mannheim (Indianapolis, IN).
  • the PI-PLC was isolated from the cultured filtrate of Bacillus cents and migrates as a single band on an
  • the sperm were capacitated overnight in 250 ⁇ l microdrops of BWW with 30 mg/ml HSA at a concentration of 20 x 10 6 sperm/ml.
  • Cumulus-oocyte complexes were collected from superovulated Golden Syrian hamsters and placed in BWW with 5 mg/ml HSA.
  • Cumulus cells were removed by treating eggs with 1 mg/ml hyaluronidase (Sigma) for 3 min. Oocytes were then washed (for this treatment and all subsequent treatments) by passing the eggs through 20 ⁇ l drops of media covered with mineral oil using a pulled, heat polished, Pasteur pipette.
  • Zonae pellucida were removed by treating eggs with 1 mg/ml trypsin (Sigma) for 30 sec followed by 5 washes.
  • 2 x 10 6 sperm were treated for 30 min. with either lU/ml PI-PLC or lU/ml of heat inactivated (95 °C for 5 min) PI-PLC in 100 ⁇ l of BWW with 30 mg/ml HSA.
  • the sperm were then washed twice by centrifugation in five ml volumes of BWW in 15 ml centrifuge tubes to remove the PI-PLC.
  • Treated sperm were then added to untreated zona-free hamster oocytes (-12 per treatment group) at a concentration of 2 X 10 6 sperm/ml in 20 ⁇ l drops of BWW with 30 mg/ml HSA and the gametes were co-incubated for 3 h.
  • sperm-egg binding and fusion - Following gamete co- incubation loosely bound sperm were removed from the oocytes by gentle pipetting. The eggs were then treated with ImM acridine orange-3% in DMSO (Sigma) for 15 sec to stain the chromatin and washed through three 20 ⁇ l microdrops. To quantitate binding, the oocytes were placed between a microscope slide and an elevated cover slip, the oocytes were visualized at 200X using a light microscope (Zeiss Axioplan) and the number of sperm bound per oocyte was recorded. The number of sperm fused per egg was scored by counting the number of acridine orange-stained decondensed sperm heads within each oocyte using fluorescent microscopy. Artificial activation of oocytes
  • zona-free eggs were treated with either lU/ml PI-PLC or lU/ml heat inactivated PI-PLC for 30 min as described in the sperm penetration assay section.
  • oocytes were preloaded with 1 ⁇ m Hoechst dye #33342 (Sigma) for 10 min to stain chromatin and washed three times.
  • the oocytes were then activated by placing the eggs in 0.5 ⁇ M calcium ionophore A23187 (Sigma) for 5 min followed by three washes.
  • the eggs were incubated for three hours and oocytes were observed as described in the sperm penetration assay section.
  • the eggs were considered activated if they had advanced from metaphase II arrest to anaphase II or telophase II (with second polar body).
  • Hamster oocytes were collected and de-zonulated as described in the sperm penetration assay section. The zona-free eggs were then washed six times in BWW media containing 100 ⁇ g/ml polyvinylalcohol (PVA, Sigma), biotinylated with 2 mg/ml Sulfo- NUS biotin (Pierce, Rockford, IL) in BWW/PVA for 7 min at room temperature, and washed six times in BWW/PVA. The eggs were then split into two groups of 130 and either mock treated or treated with lU/ml PI-PLC in 20 ⁇ l drops for 30 min. The supernatants were removed, the eggs were washed six times, and the oocytes and the oocyte supernatants were then frozen at -70 °C in BWW/PVA containing protease inhibitors
  • the membranes were blocked in PBS with 0.1 % Tween and 5% dried milk for 30 min at room temperature, washed IX in PBS/0.1% Tween, and probed with 20 ⁇ g/ml strepavidin-HRP (Pierce) for 30 min at room temperature. The blots were washed 3X in PBS/0.1%) Tween (10 min per wash) and the biotinylated proteins were visualized using TMB as a substrate.
  • the sperm penetration assay and egg activation assay were each repeated three times. Experimental and control group averages were reported as means +/- the standard deviation. Groups were compared using the students T test and differences were reported at the 0.05 level of significance.
  • a 25-40 kDa (pi 5-6) Protein Cluster is Released from Ocytes treated with PI-PLC Hamster oocytes were biotinylated and incubated with or without PI-PLC for
  • the supernatants were collected from the two groups, the eggs were washed, and the egg proteins were extracted.
  • the egg protein extracts and the proteins from the supernatants were separated by 2-D electrophoresis and electroblotted to nitrocellulose membranes.
  • the membranes were then stained with Protogold to visualize the egg proteins.
  • the membranes were probed with strepavidin-HRP and the biotinylated egg surface proteins were visualized using TMB membrane peroxidase substrate.
  • the repertoire of zona-free hamster egg proteins is shown in Fig. 11 A with over one hundred egg proteins being resolved following Protogold staining (red staining).
  • Fig. 11 A The repertoire of surface- labeled zona-free hamster egg proteins (blue staining) can also be seen in Fig. 11 A. Approximately eleven biotinylated surface protein spots having molecular weights ranging from - 40 to 140 kDa can be visualized (small arrowheads). Seven of these surface labeled protein spots were also stained with Protogold (small arrowheads labeled d). One lesser - 45-50 kDa protein cluster cl), one predominant -25-40 kDa protein cluster c2), and three protein trains having masses of - 35, 20 , and 15 kDa (t 1, 2, and 3 respectively) can be resolved.
  • the predominant 25-40 kDa protein cluster c2) can be further resolved into three smaller protein clusters, however, the clusters were not recorded as separate proteins because continuous protein staining was observed between the clusters.
  • the two spots denoted by asterisks in Fig. 10A represent proteins that bound strepavidin-HRP non- specifically and were detected on 2-D blots of oocytes which were not biotinylated.
  • the repertoire of biotin-labeled egg proteins remaining on the egg surface following PI-PLC treatment is shown in Fig. 1 lC.
  • the two arrows denote the location of the 25-40 kDa (pi 5-6) protein cluster c2) which is prominent in the extracts of untreated eggs (Fig.
  • Fig. 1 ID The train of four proteins having a mass of -29 kDa and indicated by the asterisk in Fig. 1 ID most probably represents isoforms of PI-PLC because identical staining patterns are observed when one ⁇ g ofthe PI-PLC preparation is separated on a 2-D gel and silver stained. It is possible that a small amount of unbound biotin remained associated with the biotinylated oocytes following oocyte washing and became linked to PI-PLC during oocyte treatment. This could explain why the PI-PLC isoforms appear to be dually labeled in Fig. 1 ID.
  • PI-PLC has differing effects on human sperm and hamster eggs during gamete interaction.
  • human sperm were treated with PI-PLC, washed, and incubated untreated zona-free hamster oocytes, sperm- egg binding is significantly enhanced while fusion is not effected.
  • GPI-anchored sperm surface proteins are thought to be involved in processes such as: protection of sperm from the immune response (Kirchhoff and Hale, 1996, Mol. Hum. Reprod. 2: 177-184); the acrosome reaction (Mendoza et al, 1993, J.
  • PI-PLC treatment releases GPI-anchored proteins from the sperm surface which mask molecules required for sperm-egg binding and fusion. It is known that sperm become coated with GPI-anchored proteins during passage through the epididymis (Kirchhoff and Hale, 1996, Mol. Hum. Reprod. 2: 177-184). It is possible that these proteins act as capacitating factors and are released from the sperm surface during passage through the female reproductive tract.
  • treatment of sperm with PI-PLC may have released more of these GPI-anchored capacitating proteins than were released from the control group, thus leading to enhanced sperm-egg binding. It is also possible that GPI-anchored sperm surface proteins are involved in acrosomal maintenance and loss of these proteins following PI-PLC treatment increased the percentage of acrosome reacted sperm in the PI-PLC treatment group, thus leading to enhanced binding. Studies are currently underway to establish if PI-PLC affects capacitation or the acrosome reaction.
  • the two protein clusters represent separate proteins each with multiple isoforms containing varying degrees of glycosylation while the protein trains (tl , t2, and t3) represent non-glycosylated proteins each consisting of multiple isoforms (Shackelford et al., 1980, J. Exp. Med. 151: 144-165; Negm et al., 1991, Comp. Biochem. Phys. Comp. Biochem. 99: 741-749).
  • the number of surface labeled proteins which can be visualized on the 2-D avidin blots of hamster oocytes is consistent with results obtained from one dimensional blots of surface labeled mouse (Boldt et al., 1989, Gam. Res.
  • the enzyme appears to be specifically affecting the 25-40 kDa protein cluster (c2) because the staining intensity ofthe remaining surface labeled proteins in Fig. 11C is similar to that which is seen in the untreated eggs in Fig. 11A.
  • the predominant protein cluster (c2) is PI-PLC sensitive while the less prominent protein cluster (cl) is not affected by PI-PLC treatment (see Fig. 1 IB).
  • both the 70 kDa and 35-40 kDa protein clusters are PI-PLC sensitive (see Example in Section 6).
  • ZP3 is a well known highly conserved, zona pellucida protein which has been characterized in many species and whose nucleotide and protein-coding sequences are known (for e.g., mouse GenBank Accession No. M20026; rat GenBank Accession No. Y10823; zebrafish AA566910; pig L22169; PCT patent no. WO9410304).
  • the mRNA (SEQ ID NO:l) and protein (SEQ ID NO:2) sequence of human ZP3 is shown in Fig. 12.
  • ZP3 is responsible for primary binding ofthe egg to a receptor(s) on the sperm (reviewed in McLeskey et al., 1998, Int. Rev. of Cytol. 177: 57-113). This binding event also initiates the acrosome reaction in which hydrolytic enzymes are released from the acrosomal compartment and act on the zona pellucida to facilitate penetration ofthe zona pellucida by sperm.
  • M70 is a membrane-associated GPI-linked form of ZP3.
  • Either zona-free mouse oocytes or mouse zona pellucidae were extracted in Triton-Xl 14 and the detergent and aqueous phases were isolated. The samples were subjected to SDS-PAGE and Western blot analysis using the monoclonal antibody (mAb) (IE- 10).
  • mAb monoclonal antibody
  • Figure 13 A the oolemmal form of ZP3 partitions in the detergent phase. This indicates that oolemmal ZP3 is associated with the membrane and contains a membrane-associated domain.
  • Fig. 14 localization of SP3 to the oolemma of zona-free mouse oocytes was demonstrated by immunostaining with ZP3 mAb .
  • the zonae pellucida were removed from ovulated mouse oocytes by treatment with chymotrypsin followed by mechanical agitation.
  • the eggs were first treated with lO ⁇ g/ml Hoechst dye, which stains chromatin in blue.
  • the eggs were then incubated with either 20 ⁇ g/ml rat IgG or purified anti-ZP3 mAb (IE- 10), washed 3 times, and incubated with fluorescent (CY-3)-conjugated goat anti-rat secondary antibodies.
  • oolemmal ZP3 which is stained in red, is localized to the oocytes microvillar region of oocytes. Similar results were seen when the zonae were removed with either acid Tyrodes or mechanical shearing.
  • kidney cells were transfected with full length recombinant mouse ZP3 (Genbank Accession No. M20026).
  • Mouse ZP3 was cloned into a mammalian expression vector by cleaving pZP3.4 (Ringuette et al., Dev. Biol. 127: 287-295) with Hindlll and EcoRI and ligating the ZP3- encoding fragment into a pcDNA3.1 expression vector.
  • Kidney cells were transiently transfected with the resultant construct using Transit (Panvera, Madison, Wisconsin).
  • the cells were fixed with paraformaldehyde, incubated with the anti-ZP3 mAb, IE- 10, and a fluorescently labeled secondary antibody.
  • Fig.15 punctate cell surface staining pattern can be seen on cells which expressed the cDNA, while cells not expressing ZP3 do not react with the IE- 10 mAb.
  • IE- 10 fluorescently labeled secondary antibody.
  • distinct types of punctate staining can be visualized.
  • a peptide (J peptide) corresponding to the IE- 10 mAb epitope on ZP3 was synthesized.
  • the IE- 10 mAb was incubated with either no peptide or saturating concentrations ofthe peptide prior to incubation with zona-free mouse oocytes.
  • the eggs were then washed and incubated with 5 fluorescently tagged secondary antibody.
  • Indirect immuno fluorescence images show that the peptide blocked antibody-antigen recognition, indicating that the IE- 10 mAb was specifically recognizing ZP3 on the oolemmal surface.
  • a novel sequence of a novel egg surface protein has been identified. These sequences can be used as antigenic molecules for the compositions and methods ofthe present invention.
  • Two-dimensional gel electrophoretic analysis of one thousand zona-free mouse oocytes was performed to determine the extent to which oolemmal proteins could be resolved on silver stained 2-D gels.
  • zona-pellucidae were removed from the ovulated mouse oocytes using acid Tyrodes and the egg proteins were solubilized in a non-ionic detergent/urea lysis buffer. The proteins were separated by isoelectric focusing followed by polyacrylamide gel electrophoresis. The gel was then silver stained to visualize egg proteins. Over five hundred oocyte proteins can be visualized on this gel. The approximate isoelectric points (pi) ofthe proteins and the approximate molecular masses (kDa) ofthe proteins have been determined. Most ofthe egg proteins fall within a pi range of 5-6.
  • Two-dimensional gel electrophoresis followed by avidin blotting was utilized to determine if vectorially labeled mouse oolemmal proteins could be resolved and visualized.
  • Eight hundred zona-free mouse oocytes were surface labeled with Sulfo-NHS biotin and extracted with a non-ionic detergent.
  • the extracted egg proteins were separated by 2-D electrophoresis, electroblotted to nitrocellulose membranes, probed with streptavidin-HRP, and biotinylated proteins were visualized on radiograms using enhanced chemi-luminescence.
  • the 2-D gel repertoire of biotin-labeled egg surface proteins is presented in Fig. IB.
  • At least fifty isolated protein spots can be visualized with most falling in the 35-100 kDA (pi 5-6) region ofthe blot.
  • 35-100 kDA region ofthe blot.
  • the three large protein clusters centered at -70 kDa (pi 5), 40 kDa (pi 5.5) and 27 kDa (pi 5). It is likely that these clusters represent isoforms of heavily glycosylated proteins. To our knowledge, this is the first report of surface-labeled oocyte proteins being resolved on 2-D blots.
  • microsequence information was obtained from several of the surface-labeled proteins.
  • one hundred zona-free mouse oocytes were biotinylated, separated on 2-D minigels, and the surface-labeled proteins were visualized by avidin blotting.
  • similar numbers of oocytes were separated on 2-D minigels and silver-stained.
  • Coordinates of several surface-labeled proteins directly matched those of silver-stained proteins indicating that these oocyte proteins localized to the cell surface. It is known that some glycoproteins cannot be visualized by standard silver staining techniques.
  • heterogeneous nature ofthe 70 and 35-45 kDa protein clusters suggest that these proteins may be heavily glycosylated which may account for their lack of silver staining.
  • Four putatively surface labeled proteins were chosen for microsequencing based on their consistent labeling with biotin after multiple surface- labeling experiments.
  • Microsequence data was obtained using LC-MS tandem mass spectrometry (Wilm et al . 1996). To ensure that sufficient protein concentrations would be available for this sequencing experiment, proteins from approximately 1300 zona-free oocytes were separated on a 2-D minigel and the gel was Coomassie-stained. The selected surface- labeled proteins spots were then cored from the minigel and submitted to the Mass Spectrometry Laboratory for microsequence analysis.
  • Protein # 1 Three peptide sequences were deduced from the CAD spectra of ions from the tryptic digest of Protein #1. Database searches using Sequest could not identify these peptides in any database sequence. To validate the authenticity of these peptide sequences, protein # 1 was cored from another Coomassie stained gel containing similar numbers of extracted oocytes and re-submitted to the Mass Spectrometry Lab for microsequencing and identical results were obtained. Therefore, protein # 1 is novel and a prime candidate for cloning and characterization.
  • M(o) designates oxidized M
  • the chaperone proteins are not released from the plasma membrane complexes with which they are assembling and are carried to the cell surface where they may be engaged in alternate functions than those which they perform in the ER.
  • BIP, calnexin, and calreticulin assist in assembly ofthe T-cell antigen receptor complex (TCR) in the ER (Van Leeuwen and
  • calnexin maintains its association with CD3 (a component ofthe TCR) and the complex is expressed on the cell membrane of immature thymocytes where it is thought to play a role in cell signaling (Wiest et al, 1995, EMBO J. 14:3424-33).
  • the highly conserved heat shock protein (HSP) family has generally been
  • HSPs are thought to actually function as antigen presenting molecules (Multhoff et al, 1995, Int. J. Cancer, 10:272-9). They are also present on the surface of T- cells and mononuclear cells which are undergoing apoptosis (Poccia et al, 1996, Immunology, 88:6-12). HSPs have also been implicated in fertilization (Boulanger et al, 1995a, J. Cell Physiol. 165:7-17).
  • the gene encoding the egg plasma membrane receptor for sperm was cloned in the sea urchin and the extracellular domain ofthe receptor is similar to the HSP70 family of proteins (Foltz et al, 1993, Zygote, 1 :276-9). Heat shock proteins have also been found on the surface of sperm by our lab and others (Boulanger et al, 1995b, supra). Regarding BIP specifically, one function of this molecule is known to bind to and assist in the finding that one ofthe surface-localized oocyte proteins was calreticulin was of particular interest. Following the acrosome reaction, calreticulin is expressed on the plasma membrane overlying the equatorial segment of sperm.
  • Clq-R the cell surface protein, Clq-R, was found to have almost complete amino acid sequence identity with calreticulin (Stuart et al, 1997). Clq-R is a receptor for Clq, a component ofthe classical complement pathway and has been found on many cell types (Peterson et al, 1997) including oocytes(Fusi et al, 1991) and sperm (Branson et al, 1998).
  • cell-surface calreticulin One known function of cell-surface calreticulin is to mediate adhesion to extracellular matrix proteins such as laminin and fibrinogen (Gray et al, 1995; McDonnell et al, 1996; White et al, 1995). This adhesion process is thought to occur in association with integrins such as ⁇ 6 ⁇ l (Zhu et al, 1997).
  • the specificity ofthe rabbit polyclonal antibody to full length recombinant calreticulin used for the subsequent assays was confirmed by probing a 2-D blot of zona- free mouse oocytes. The blot was first stained with Protogold to visualize oocyte proteins (Fig. 3A). Immunoblotting revealed that the calreticulin antibodies are highly specific and recognize only two oocyte proteins, calreticulin and calnexin (Fig. 3B, arrows). It is not surprising that the calreticulin polyclonal antibody also recognized calnexin because calnexin is the membrane bound homologue of calreticulin.
  • Fig. 3C highlights the observation that both calreticulin and calnexin were surface- labeled with biotin.
  • the oocyte cell surface localization of calreticulin was then confirmed by indirect immunofluorescence. A greater fluorescence staining intensity was observed on live zona-free oocytes that were incubated with fluorescent beads coated with a 1-50 dilution of calreticulin antisera when compared to oocytes incubated with beads coated with a similar dilution of normal rabbit sera.
  • calreticulin antibodies were then investigated in an in vitro fertilization assay.
  • Cumulus-free zona-intact mouse oocytes were either not treated with antibodies or treated with a 1 :50 dilution of normal rabbit sera or anti-calreticulin antibodies.
  • the eggs were then washed and inseminated with untreated mouse epididymal sperm. Following overnight incubation, oocytes which had not undergone cleavage were scored as unfertilized and oocytes which bad cleaved were scored as fertilized.
  • Significantly fewer (p ⁇ 0.05) oocytes underwent cleavage following incubation with calreticulin antibodies (1.3%) when compared to oocytes which were either not treated (68%) or treated with normal rabbit sera (75%).
  • calreticulin has been shown to modulate calcium transients following engagement of surface integrins (Coppolino et al, 1997) and when calcium transients are blocked, fertilization becomes arrested following sperm-egg fusion in both sea urchins (Lee and Shen, 1998) and mice (Xu et al., 1994).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des antigènes de la surface de l'ovocyte utiles pour la production d'anticorps capables de se lier aux épitopes présents au niveau de la surface de l'ovocyte et de moduler ainsi la fécondité. L'invention concerne des compositions et des méthodes d'immunisation d'un individu en vue de la production d'anticorps dirigés contre les antigènes de la surface de l'ovocyte. L'invention se fonde sur la découverte d'antigènes de la surface de l'ovocyte impliqués dans la liaison et la fusion ovocyte-sperme. L'invention concerne des méthodes d'utilisation de ces antigènes dans des techniques de stérilisation d'animaux femelles. L'invention concerne aussi des méthodes d'utilisation des antigènes de la surface de l'ovocyte pour générer des anticorps utiles dans des méthodes de contraception réversibles et temporaires. L'invention concerne enfin des méthodes d'utilisation d'anticorps monoclonaux anti-idiotypiques qui imitent les épitopes de la surface de l'ovocyte pour immuniser activement un mammifère contre la fécondation.
PCT/US1999/013858 1998-06-19 1999-06-18 Proteines de la surface de l'ovocyte et methodes de modulation de la fecondite WO1999065520A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP99930430A EP1085903A1 (fr) 1998-06-19 1999-06-18 Proteines de la surface de l'ovocyte et methodes de modulation de la fecondite
AU46974/99A AU4697499A (en) 1998-06-19 1999-06-18 Egg surface proteins and methods for use for modulating fertility
JP2000554398A JP2002518344A (ja) 1998-06-19 1999-06-18 卵表面タンパク質及び受精調節のためのその使用方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8995098P 1998-06-19 1998-06-19
US60/089,950 1998-06-19

Publications (1)

Publication Number Publication Date
WO1999065520A1 true WO1999065520A1 (fr) 1999-12-23

Family

ID=22220352

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/013858 WO1999065520A1 (fr) 1998-06-19 1999-06-18 Proteines de la surface de l'ovocyte et methodes de modulation de la fecondite

Country Status (4)

Country Link
EP (1) EP1085903A1 (fr)
JP (1) JP2002518344A (fr)
AU (1) AU4697499A (fr)
WO (1) WO1999065520A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053339A3 (fr) * 2000-01-20 2002-02-28 Univ Virginia Proteines de surface specifiques de l'oeuf
WO2003021274A3 (fr) * 2001-09-04 2003-11-27 Xzillion Gmbh & Co Kg Procede pour separer des macromolecules ayant subi une modification chimique reversible
EP1587833A4 (fr) * 2003-01-10 2006-03-22 Univ Virginia Epad, une proteine a oocyte specifique
US7019114B2 (en) 1998-02-19 2006-03-28 Eastern Virginia Medical School Recombinant, biologically active human zona pellucida protein 3 (HZP3) to test male fertility
US7037663B2 (en) 1998-02-19 2006-05-02 Eastern Virginia Medical School Human zona pellucida protein 3 and uses thereof
US7148021B2 (en) 2001-08-02 2006-12-12 Eastern Virginia Meical School Human zona pellucida proteins and methods of their use in diagnosing male infertility
WO2008026906A1 (fr) * 2006-08-25 2008-03-06 Instituto Nacional De Ciencias Médicas Y Nutrición Salvador Zubirán Essai de capture de spermatozoïdes utilisant les protéines zp2, zp3 et zp4
WO2014120975A1 (fr) * 2013-02-01 2014-08-07 California Institute Of Technology Immunocontraception à médiation par un anticorps
US10966414B2 (en) 2015-05-26 2021-04-06 California Institute Of Technology Population control using engineered translocations
US11965172B2 (en) 2018-11-05 2024-04-23 California Institute Of Technology DNA sequence modification-based gene drive
US12157883B2 (en) 2017-05-05 2024-12-03 California Institute Of Technology DNA sequence modification-based gene drive

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641487A (en) * 1989-06-12 1997-06-24 The Government Of The United States Of America As Represented By The Secretary Department Of Health And Human Services Contraceptive vaccine based on alloimmunization with zona pellucida polypeptides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641487A (en) * 1989-06-12 1997-06-24 The Government Of The United States Of America As Represented By The Secretary Department Of Health And Human Services Contraceptive vaccine based on alloimmunization with zona pellucida polypeptides

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7019114B2 (en) 1998-02-19 2006-03-28 Eastern Virginia Medical School Recombinant, biologically active human zona pellucida protein 3 (HZP3) to test male fertility
US7037663B2 (en) 1998-02-19 2006-05-02 Eastern Virginia Medical School Human zona pellucida protein 3 and uses thereof
US6962988B2 (en) 2000-01-20 2005-11-08 University Of Virginia Patent Foundation Egg specific surface proteins
WO2001053339A3 (fr) * 2000-01-20 2002-02-28 Univ Virginia Proteines de surface specifiques de l'oeuf
US7148021B2 (en) 2001-08-02 2006-12-12 Eastern Virginia Meical School Human zona pellucida proteins and methods of their use in diagnosing male infertility
WO2003021274A3 (fr) * 2001-09-04 2003-11-27 Xzillion Gmbh & Co Kg Procede pour separer des macromolecules ayant subi une modification chimique reversible
EP1587833A4 (fr) * 2003-01-10 2006-03-22 Univ Virginia Epad, une proteine a oocyte specifique
WO2008026906A1 (fr) * 2006-08-25 2008-03-06 Instituto Nacional De Ciencias Médicas Y Nutrición Salvador Zubirán Essai de capture de spermatozoïdes utilisant les protéines zp2, zp3 et zp4
WO2014120975A1 (fr) * 2013-02-01 2014-08-07 California Institute Of Technology Immunocontraception à médiation par un anticorps
US10570200B2 (en) 2013-02-01 2020-02-25 California Institute Of Technology Antibody-mediated immunocontraception
US10966414B2 (en) 2015-05-26 2021-04-06 California Institute Of Technology Population control using engineered translocations
US12213468B2 (en) 2015-05-26 2025-02-04 California Institute Of Technology Population control using engineered translocations
US12157883B2 (en) 2017-05-05 2024-12-03 California Institute Of Technology DNA sequence modification-based gene drive
US11965172B2 (en) 2018-11-05 2024-04-23 California Institute Of Technology DNA sequence modification-based gene drive

Also Published As

Publication number Publication date
JP2002518344A (ja) 2002-06-25
AU4697499A (en) 2000-01-05
EP1085903A1 (fr) 2001-03-28

Similar Documents

Publication Publication Date Title
Coonrod et al. Treatment of mouse oocytes with PI-PLC releases 70-kDa (pI 5) and 35-to 45-kDa (pI 5.5) protein clusters from the egg surface and inhibits sperm–oolemma binding and fusion
Hao et al. SAMP32, a testis-specific, isoantigenic sperm acrosomal membrane-associated protein
FI121366B (fi) Uusia siiliperäisiä polypeptidejä
Lin et al. A hyaluronidase activity of the sperm plasma membrane protein PH-20 enables sperm to penetrate the cumulus cell layer surrounding the egg.
EP0876612B1 (fr) Procede d'identification de molecules specifiques au sexe et aux especes, molecules identifiees grace a ce procede et utilisations de ces molecules
US6797480B1 (en) Purification of heat shock/stress protein cell surface receptors and their use as immunotherapeutic agents
US20130230918A1 (en) Novel collectin
Saitoh et al. Direct and indirect association of the small GTPase ran with nuclear pore proteins and soluble transport factors: studies in Xenopus laevis egg extracts.
EP1085903A1 (fr) Proteines de la surface de l'ovocyte et methodes de modulation de la fecondite
Naz et al. Molecular cloning and sequencing of cDNA encoding for human FA‐1 antigen
US20030162238A1 (en) Sex-chromosome-specific proteins, species specific and sperm specific proteins and methods for their identification and isolation
US20030143712A1 (en) Histone deacetylase and methods of use thereof
US20090186029A1 (en) Antibodies that specifically bind hedgehog-derived polypeptides
US20060172300A1 (en) Method for identifying bhs-specific proteins and fragments thereof
WO2002018418A1 (fr) Anticorps specifiques aux lysines methylees dans des histones
WO1997017444A2 (fr) Nouveaux recepteurs du sperme
CA2443341A1 (fr) Gene humain essentiel pour la fertilite
AU782467B2 (en) Egg specific surface proteins
US6214794B1 (en) Method of using hedgehog polypeptides to regulate neuronal cell growth
US20060078953A1 (en) Epad, an oocyte specific protein
Lin Characterization of the biological activities of recombinant fusion protein green fluorescent protein/human zona pellucida protein 3 (GFP/HZP3)
Kuscuoglu Isolation and characterization of genes involved in glucocorticoid-induced thymocyte apoptosis
JP2001514743A (ja) 細胞表面タンパク質に対するワクチンの製造方法
Grootenhuis et al. Recombinant human zona pellucida protein ZP3 produced by chinese hamster ovary cells induces the human sperm acrosome reaction and promotes sperm-egg fusion
Naz applications in infertility and immunocontraception

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 554398

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999930430

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999930430

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999930430

Country of ref document: EP